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Abstract 
 
Leptin and insulin are key hormonal regulators of energy balance and glucose 
homeostasis.  SH2B1 is a PH- and SH2-domain containing adapter protein that promotes 
both leptin and insulin signaling in cells.  Disruption of Sh2b1 in mice causes obesity and 
diabetes, providing genetic evidence that SH2B1 is an essential regulator of energy 
balance and glucose homeostasis.  Here, the contribution of SH2B1 in brain, peripheral 
tissues, and islets to the regulation of insulin sensitivity and glucose homeostasis was 
examined in vivo.  Reconstitution of full length SH2B1, but not the SH2 domain alone, in 
neurons in Sh2b1-deficient mice was sufficient to prevent the development of obesity and 
insulin resistance.  By contrast, expression of a mutant form of SH2B1 that lacked a 
functional SH2 domain in neurons of wild type mice promoted weight gain and impaired 
whole body insulin sensitivity.  Thus, SH2B1 in the brain indirectly regulates glucose 
homeostasis by controlling energy balance and body weight.  To address the role of 
peripheral SH2B1 in the regulation of insulin sensitivity and glucose metabolism, mice 
expressing SH2B1 in the brain but not in peripheral tissues (TgKO mice), were fed a high 
fat diet (HFD).  Deletion of SH2B1 in peripheral tissues did not alter HFD-induced 
obesity, but significantly exacerbated HFD-induced hyperglycemia, hyperinsulinemia 
and glucose intolerance in TgKO mice.  Insulin signaling was attenuated in muscle, liver, 
and white adipose tissue from HFD-fed TgKO mice.  In cultured cells, SH2B1 binds to 
the insulin receptor, IRS-1 and IRS-2, and enhances insulin sensitivity by both promoting 
receptor activity and by inhibiting tyrosine dephosphorylation of IRS proteins, providina 
mechanism by which SH2B1 likely promotes insulin action in these tissues.  SH2B1 also 
promotes glucose homeostasis independent of central leptin action.  Leptin-deficient 
(ob/ob) mice with Sh2b1 haploinsufficiency (Sh2b1+/-ob/ob) developed severe 
hyperglycemia and glucose intolerance.  Plasma insulin levels and pancreatic insulin 
content were reduced in Sh2b1+/-ob/ob mice.  SH2B1 is highly expressed in pancreatic 
islets, and these data suggest that SH2B1 in islets may regulate glucose homeostasis by 
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promoting insulin biosynthesis and secretion.  Together, these findings indicate that 






Overnutrition and increasingly sedentary lifestyles have led to an increased 
prevalence of obesity and obesity-associated metabolic diseases, including type 2 
diabetes (or non-insulin dependent diabetes mellitus (NIDDM)).  Obesity is primarily 
caused by long-term energy imbalance, which occurs when energy (food) intake exceeds 
metabolic expenditure.  Excess energy is stored as trglyceride in adipose tissue, causing 
an increased in adiposity and weight gain.  Increased adiposity that is associated with 
excessive weight gain is now considered a driving force for the development of type 2 
diabetes.  Increased adiposity is associated with an increase in pro-inflammatory cytokine 
production and a state of low grade, chronic inflammation.  Systemic increases in pro-
inflammatory cytokines causes impaired insulin action in peripheral tissues (insulin 
resistance).  Insulin resistance contributes to the development of impaired glucose 
tolerance and hyperglycemia, and may eventually cause -cell failure, the determinant 
type 2 diabetes. 
Both obesity and type 2 diabetes are complex polygenic disorders, and the 
interaction of multiple factors contributes to the onset and severity of both diseases.  
Interactions between environmental risk factors (e.g. increasing sedentary lifestyle, 
overnutrition, and aging) and genetic susceptibility contribute to the development of 
obesity and diabetes.  While the environmental component is difficult to quantify, it is 
clear that genetic susceptibility is a key determinant.  Factors associated with obesity and 
diabetes, including dyslipidemia, hypertension, and adiposity, are highly heritable in man 
(220).  However, single gene defects only explain a small proportion of all cases of 
obesity and diabetes (88, 89, 172, 189).  These findings suggest that dysfunction or 
aberrant regulation of multiple genes, which by themselves have relatively small effect, 
likely interact with obesogenic and/or diabetogenic factors to promote energy imbalance 
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and/or impaired glucose tolerance.  Therefore, identification and characterization of 
obesity- and diabetes-susceptibility genes promises to increase not only our basic 
understanding of the pathophysiology involved in these disease processes, but also 
increase the potential therapeutic options for treatment of these comorbidities.  Mounting 
evidence suggests that the adapter protein SH2B1 is a candidate susceptibility gene for 
obesity and diabetes in man, and a novel positive regulator of both leptin and insulin 
action in mammals. 
Central leptin action regulates energy balance and body weight 
Body weight is normally maintained within a narrow range by a sophisticated 
neuroendocrine system that constantly monitors energy storage, availability, and 
consumption.  When energy intake (food intake) exceeds metabolic demand 
(expenditure), excess energy is assimilated into triglyceride in adipose tissue.  This leads 
to increased adiposity and weight gain.  If this energy balance is not corrected, obesity 
and obesity-associated metabolic diseases ensue. 
Communication between adipose tissue, which is the primary energy storage 
depot in mammals, and the brain is important for the long-term regulation of energy 
balance and body weight.  While the primary function of adipose tissue is to store excess 
energy as neutral lipid, adipose tissue is also a key endocrine organ.  In obese individuals, 
adipose tissue becomes the largest endocrine tissue in the body.  Adipose tissue secretes 
many cytokines (also referred to adipokines), including leptin.  Leptin- or leptin-receptor 
(LEPR) deficiency causes morbid obesity and metabolic syndrome in both animals and 
humans (42, 156, 214, 219, 250), indicating that leptin plays an essential role in the 
regulation of energy balance and body weight.  Leptin is secreted in direct proportion to 
adipose mass and serum leptin levels rise as triglyceride accumulates in adipose depots 
(32, 86, 176, 213).  Thus, leptin levels signal the relative storage and availability of 
energy. 
The brain senses leptin and various other metabolic signals and integrates these 
signals into appropriate physiological responses to regulate energy homeostasis and body 
weight.  Central administration of recombinant leptin reduces food intake and body 
weight in rodents (32, 85, 213).  Neuron-specific deletion of LEPR in mice results in 
obesity (43), whereas neuron-specific restoration of functional LEPR rescues the obese 
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phenotype in LEPR-null (db/db) mice (51, 122).  These data indicate that leptin acts on 
neurons in the brain to suppress food intake and promote energy expenditure. 
Leptin acts on multiple neuronal populations in the brain 
LEPR mRNA is highly expressed in multiple regions of the brain, including the 
arcuate nucleus (ARC), the ventromedial (VMH), dorsomedial hypothalamic nuclei 
(DMH), ventral tegmental area (VTA), hippocampus, and the brainstem (38, 62, 63, 71, 
84, 97, 149, 151, 202, 203).  Leptin induces expression of c-Fos, a marker of neuronal 
activity, and activates signal transducer and activator of transcription 3 (STAT3) in 
hypothalamic neurons known to control energy intake and expenditure, such as the ARC, 
VMH, and DMH (60, 62, 101, 162).  However, restoration of LEPR expression 
specifically in the ARC corrects hyperphagia and obesity in LEPR-null rats, suggesting 
that the ARC is a key leptin target (202).  Two subpopulations of neurons in the ARC 
(POMC-neurons and AgRP-neurons) have emerged as critical mediators for leptin action. 
POMC-neurons coexpress two anorexigenic neuropeptides: proopriomelanocortin 
(POMC) and cocaine- and amphetamine-regulated transcript (CART) (61, 202).  POMC 
is proteolytically cleaved to generate -melanocyte stimulating hormone (-MSH) which 
activates melanocortin-3 and melanocortin-4 receptors (MC3R and MC4R) (35, 67, 72, 
102, 191).  MC3R and MC4R are G protein-coupled receptors that are highly expressed 
in the hypothalamus, especially in the paraventricular hypothalamus (PVN).  Deletion of 
either MC3R or MC4R results in leptin resistance and obesity in mice (35, 102).  
Additionally, genetic defects in either the POMC or the MC4R genes are linked to obesity 
in humans (42, 124). 
AgRP-neurons coexpress two orexigenic neuropeptides: agouti-related protein 
(AgRP) and neuropeptide Y (NPY) (83, 202).  NPY potently stimulates feeding behavior 
and food intake (212).  AgRP is a potent antagonist of both MC3R and MC4R (174).  
Hypothalamic AgRP-neurons are required for feeding in adult mice (82, 143).  
Interestingly, leptin has opposing effects on POMC- and AgRP-neurons in the 
hypothalamus.  Leptin stimulates excitability and expression of POMC and CART in 
POMC-neurons; conversely, leptin inhibits both excitability and NPY/AgRP expression 
in AgRP-neurons (49, 61, 123, 155, 202, 203, 209, 213, 215). 
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The differential regulation of excitability in NPY/AgRP and POMC neurons can 
be explained, at least in part, by differential modulation of KATP channels by leptin and 
other factors, including insulin and glucose (135, 175, 209, 210).  Leptin-induced 
hyperpolarization of NPY/AgRP-neurons inhibits neuronal activity, which is supported 
by the observation that leptin fails to induce c-Fos expression in NPY/AgRP-neurons 
(60).  Others have proposed that leptin directly increases the action potential frequency in 
POMC neurons by both regulating a nonspecific cation channel and by reducing the 
inhibitory tone of POMC neurons, which is imposed by GABA release from either 
NPY/AgRP neurons or inhibitory interneurons within the ARC (48, 49).  However, 
POMC neurons have also been shown to be glucose- and insulin-responsive (103, 135, 
175, 240), and it is likely that POMC neurons integrate multiple metabolic cues and 
synaptic inputs with leptin signaling to regulate energy balance. 
Surprisingly, selective deletion of functional LEPR in either AgRP- or POMC-
neurons results in mild obesity (9, 226).  Deletion of LEPR in both AgRP- and POMC-
neurons has an additive effect in terms of body weight and adiposity; however, the 
metabolic phenotypes in these double mutant mice are still milder than in systemic 
LEPR-deficient db/db mice (226).  Interestingly, whereas db/db mice remain severely 
hyperphagic throughout life, mice lacking LEPR in both AgRP- and POMC- neurons 
initially exhibit periweaning hyperphagia (4-6 wks of age), but food intake gradually 
returns to wild type levels in adulthood (226).  These observations suggest that leptin also 
acts on extraarcuate neurons to regulate energy balance and body weight.  In the VMH, 
leptin activates steroidogenic factor-1 (SF1)-positive neurons and selective deletion of 
LEPR in this population increases susceptibility to diet-induced obesity (21, 54).  
Additionally, leptin suppresses motivated food-seeking behaviors by activating STAT3 in 
dopaminergic and GABAnergic neurons in the VTA (71, 97).  These distinct leptin-
responsive neurons may act redundantly, in parallel, and/or synergistically with 
hypothalamic neurons to fully mediate leptin action.  Unraveling the complexities of 
these and other leptin-regulated neuronal networks will not only provide further insight 
into regulation of energy balance and feeding behavior by leptin, but will also likely 
increase our understanding of the role of leptin in other aspects of physiology, including 
reproduction and motivated behaviors as indicated by recent reports (133, 134, 164). 
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Leptin stimulates multiple signal transduction pathways 
The LEPR gene produces multiple leptin receptor isoforms (a, b, c, d, and e) via 
alternative mRNA splicing (27, 64, 69, 151).  All isoforms have an extracellular leptin-
binding domain, but only the longest form, LEPRb, contains a full-length intracellular 
domain required for cellular signaling (70).  LEPRa lacks the entire cytoplasmic domain 
and is thought to mediate leptin transport across the blood brain barrier (94, 95).  Genetic 
deficiency of LEPRb results in profound leptin resistance and morbid obesity in animals, 
indicating that LEPRb is required for leptin action (14, 36, 41, 77, 128).  LEPRb belongs 
to the gp130 family of cytokine receptors (14, 36, 77).  It constitutively binds to JAK2, a 
member of the Janus kinase (JAK) family of tyrosine kinases.  Leptin stimulates LEPRb 
dimerization, resulting in JAK2 activation and autophosphorylation (10, 52, 66, 232).  
JAK2 also phosphorylates LEPRb and various downstream signaling molecules on 
tyrosines (25, 76, 113).  JAK2 phosphorylates Tyr985, Tyr1077 and Tyr1138 in the 
cytoplasmic domain of LEPRb, which then act as docking sites for downstream signaling 
molecules (10, 90, 136).  Replacement of these three tyrosines with phenylalanines in 
LEPRb induces marked leptin resistance and obesity in mutant mice, indicating that 
phospho-Tyr985, -Tyr1077 and/or -Tyr1138 mediate the activation of key downstream 
pathways; however, the mutant mice are less obese and less hyperglycemic than LEPRb-
deficient db/db mice, indicating that LEPRb can mediate some of leptin’s action 
independent of phosphorylation on these tyrosines (107). 
STAT family members are SH2 domain-containing transcription factors located 
in the cytoplasm in quiescent cells.  Cytokine-stimulated tyrosine phosphorylation of 
STATs induces homo- or heterodimerization, nuclear translocation and transcriptional 
activation (98).  Leptin stimulates tyrosine phosphorylation of STAT1, 3, 5 and 6 in 
cultured cells (14, 77, 192, 217); however, only STAT3 and STAT5 phosphorylation has 
been documented in the hypothalamus of leptin-treated rodents (80, 148, 225).  Tyr1138 in 
LEPRb is within an YXXQ motif, a consensus binding motif for STAT3 (211).  In 
response to leptin, STAT3 binds to phospho-Tyr1138, allowing JAK2 to phosphorylate and 
activate STAT3.  Mutation of Tyr1138 abolishes the ability of leptin to activate the STAT3 
but not other pathways in both cultured cells and mice (10, 13, 232).  Disruption of the 
STAT3 binding site in LEPRb, or deletion of STAT3 in leptin-responsive neurons, causes 
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severe hyperphagia and morbid obesity in mice (12, 13, 50, 73, 79, 107, 178, 241).  These 
data indicate that the LEPRb/JAK2/STAT3 pathway in the brain is required for the anti-
obesity actions of leptin. 
Leptin also stimulates phosphorylation of LEPRb on Tyr1077 which recruits 
STAT5 and mediates STAT5 phosphorylation (80, 90, 163).  Deletion of both STAT5A 
and STAT5B in the brain causes leptin resistance, hyperphagia and obesity, but to a 
lesser extent than STAT3 deletion (130).  These findings suggest that activation of the 
LEPRb/JAK2/STAT3 pathway is also required for the anti-obesity actions of leptin. 
Leptin promotes the activation of phosphoinositide-3 kinase (PI3K) in cultured 
cells and in the hypothalamus (18, 116, 240, 253).  JAK2 phosphorylates insulin receptor 
substrate-2 (IRS-2) on tyrosines, which recruits the p85 regulatory subunit of PI3K.  
Inhibition of the PI3K pathway in the brain blocks the ability of leptin to reduce food 
intake and weight gain in rodents (170, 252).  Likewise, deletion of IRS-2, either 
systemically or in hypothalamic neurons, results in hyperphagia and obesity in mice (31, 
125, 140, 145).  PI3K activity is negatively regulated by PTEN (Phosphatase and Tensin 
homolog deleted on chromosome Ten), and deletion of PTEN specifically in LEPR-
expressing neurons increases leptin sensitivity and reduces adiposity (180).  Several 
proteins have been implicated as downstream targets of the JAK2/IRS-2/PI3K pathway.  
These include FOXO1, phosphodiesterase 3, and ATP-sensitive potassium channels (115, 
117, 154, 179, 252).  Collectively, these findings indicate that the JAK2/IRS-2/PI3K 
pathway is required for leptin’s anorexigenic actions. 
SH2-containing protein tyrosine phosphatase 2 (SHP2) is a ubiquitously 
expressed cytoplasmic protein-tyrosine phosphatase that contains two N-terminal SH2 
domains and one C-terminal phosphatase domain.  SHP2 binds via its SH2 domain to 
phosphorylated Tyr985 in LEPR and leptin stimulates ERK1/2 activation via 
phosphorylation of SHP2 in cultured cells and the hypothalamus (22, 34, 136, 184, 216, 
248).  Neuron-specific deletion of SHP2 results in obesity (248), and pharmacological 
inhibition of ERK1/2 in the hypothalamus also abrogates the ability of leptin to inhibit 
food intake and block weight gain (184).  Thus, the SHP2/MAPK pathway is involved in 
mediating leptin’s anorexigenic action in vivo. 
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Our laboratory has also reported that leptin stimulates the STAT3 and the MAPK 
pathways in cells that are genetically deficient of JAK2 (106).  The Src tyrosine kinase 
family members appear to be involved in mediating JAK2-independent leptin signaling 
(15, 106, 157).  Interestingly, overexpression of kinase-inactive JAK2 enhances leptin 
signaling in JAK2-deficient cells, suggesting that JAK2 functions both as a tyrosine 
kinase and as an adaptor to transduce leptin signals (106).  The JAK2-dependent and 
JAK2-independent pathways appear to act synergistically to mediate leptin responses 
(106).  However, the physiological importance of the JAK2-independent pathway has not 
been verified in animals. 
These diverse leptin signaling pathways form a network that regulates neuronal 
activity in the hypothalamus to fully mediate the physiological responses to leptin.  This 
signaling network may be differentially regulated in different hypothalamic neurons with 
varying degrees of cross talk and synergy between individual pathways.  Additionally, 
individual pathways in this network may contribute differently to the regulation of 
various populations of LERPb-expressing neurons. 
Central leptin resistance contributes to obesity 
Obese individuals produce excessive amounts of leptin (hyperleptinemia), yet 
leptin apparently fails to reach or activate its hypothalamic targets (45, 87, 144).  
Moreover, with the exception of rare monogenic forms of leptin deficiency, leptin 
treatment fails to induce weight loss in nearly all cases of obesity (93).  These 
observations have given rise to the concept that leptin resistance is a driving force in 
pathogenesis of obesity in man.  Many factors likely contribute to leptin resistance, 
including impaired leptin transport into the brain and impaired activation of leptin signal 
transduction pathways. 
Blood-borne proteins, including leptin, are separated from the brain by the blood-
brain barrier (BBB), which is formed by tight junctions in the cerebral endothelium 
(199).  Leptin is transported across the BBB by a saturable transport mechanism (11).  A 
role for LEPRa in leptin transport has been suggested based on the observation that 
LEPRa is highly expressed in brain microvessels and in the choroid plexus (24, 94, 95, 
110).  However, circumventricular organs lack tight junctions characteristic of the BBB 
(199).  Many of the leptin-responsive neurons in the hypothalamus lie near the highly 
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vascularized median eminence, which is outside the BBB.  This raises the possibility that 
leptin may also freely diffuse from the circulation to leptin-sensitive neurons in the 
hypothalamus.  Regardless, obese humans have a reduced cerebrospinal fluid-to-serum 
ratio for leptin, suggesting that reduced leptin transport into the brain contributes to 
obesity (33, 58, 201).  Moreover, intracerebroventricular leptin injections more potently 
inhibit food intake than peripheral leptin administration, particularly in obese rodents (32, 
85, 86, 176, 227).  Collectively, these findings suggest that impaired leptin transport into 
the brain contributes to leptin resistance and may be a driving force in the development of 
obesity; however, it remains unclear whether leptin transport defects predispose to 
obesity or are acquired with the onset of obesity. 
Leptin resistance may also be caused by diminished leptin signaling in 
hypothalamic neurons.  Leptin-stimulated activation of the JAK2/STAT3 and the 
JAK2/IRS-2/PI3K pathways in hypothalamic neurons is negatively regulated by 
suppressor of cytokine signaling 3 (SOCS3) and protein tyrosine phosphatase 1B 
(PTP1B) (16, 26, 28, 37, 112, 165, 245).  Leptin stimulates SOCS3 expression via the 
JAK2/STAT3 pathway in cultured cells as well as in the hypothalamus (26).  SOCS3 
provides a critical negative feedback mechanism to prevent over-activation of leptin 
signaling pathways in the brain.  SOCS3 binds to JAK2 and inhibits JAK2 activity (26).  
Additionally, SOCS3 binds to phospho-Tyr985 in LEPRb and inhibits leptin signaling (28, 
66).  As expected, neuron-specific deletion of SOCS3 enhances leptin sensitivity in mice 
(158), and SOCS3 haploinsufficiency protects mice from dietary fat-induced leptin 
resistance and obesity (100).  Furthermore, mutation of Tyr985 in LEPRb, the binding site 
for SOCS3, increases leptin sensitivity in mice (29).  SOCS3 expression is significantly 
increased in the hypothalamus in leptin resistant animals, suggesting that increased 
SOCS3 expression contributes to leptin resistance (23, 65, 161, 177).  
PTP1B binds to and dephosphorylates JAK2, thereby inhibiting leptin signaling 
(112, 165, 245).  PTP1B is expressed in the ARC, VMH and DMH (245).  Both systemic 
and neuron-specific deletion of PTP1B improves leptin sensitivity and reduces adiposity 
in mice (16, 37, 245).  The expression of hypothalamic PTP1B is increased in leptin 
resistant animals, suggesting that PTP1B also contributes to leptin resistance (160, 231).  
Interestingly, overexpression of the JAK2 binding protein, SH2B1, counteracts PTP1B-
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mediated inhibition of leptin signaling in cultured cells (185).  Therefore, cellular leptin 
sensitivity may be determined, at least in part, by a balance between positive (e.g. 
SH2B1) and negative (e.g. SOCS3 and PTP1B) regulators.  
The SH2-B family of adapter proteins mediate cell signaling 
The SH2-B family of adapter proteins consists of three members (SH2B1, SH2B2 
(APS) and SH2B3 (Lnk)) that are encoded by different genes (147).  SH2B proteins are 
structurally similar in that all have an N-terminal dimerization domain (DD), multiple 
proline-rich regions, a central pleckstrin homology (PH) domain, and a C-terminal Src 
homology 2 (SH2) domain.  Additionally, SH2B1 also has a nuclear localization signal 
(NLS) between the DD and PH domains (146). 
The expression of SH2B3 is restricted to hematopoietic tissues and SH2B3 
negatively regulates hematopoiesis (218, 228, 243).  By contrast, SH2B1 and SH2B2 are 
expressed in multiple tissues, including brain, skeletal muscle, liver, white and brown 
adipose tissue, pancreas, and spleen (56, 153, 185).  Four forms of SH2B1 (, , , and ) 
and two forms of SH2B2 ( and ) have been identified (137, 168).  All four variants of 
SH2B1 have the complete DD, NLS, PH and SH2 domains but their respective N-termini 
differ due to alternative mRNA splicing (168).  Because the key functional domains are 
conserved, SH2B1 variants are predicted to have similar and/or overlapping functions.  
SH2B2 also has conserved DD, PH and SH2 domains; however, a naturally occurring 
truncated form of SH2B2 (SH2B2) has also been identified (137).  SH2B2 has both 
DD and PH domains, but lacks the C-terminal SH2 domain (137). 
SH2B1 and SH2B2 proteins have been implicated as signaling molecules for a 
host of growth factors and cytokines.  This list includes leptin, insulin, growth hormone 
(GH), insulin-like growth factor 1 (IGF-1), fibroblast growth factor (FGF), platelet-
derived growth factor (PDGF), nerve growth factor (NGF), brain-derived neurotrophic 
factor (BDNF), and glial-cell-line-derived neurotrophic factor (GDNF) (55, 120, 121, 
139, 183, 190, 193-195, 229, 251).  In general, SH2B1 and SH2B2 enhance cell 
signaling, which promotes various cellular responses ranging from mitogenesis to 
glucose uptake to neurite outgrowth and neuronal differentiation. 
Identification of SH2B1 as an endogenous leptin sensitizer 
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To examine the physiological functions of SH2B1, two groups have 
independently disrupted the Sh2b1 gene in mice by homologous recombination (56, 173).  
SH2B1-knockout (KO) mice are obese and develop insulin resistance (56, 138, 185).  
SH2B1-KO are hyperleptinemic and leptin treatment fails to induce weight loss (185), 
indicating that SH2B1 is required for leptin action in vivo.  Interestingly, neuron-specific 
reconstitution of SH2B1 in KO mice rescues obesity by improving leptin responses 
(186).  Moreover, overexpression of SH2B1 in neurons prevents diet-induced leptin 
resistance and obesity (186).  Collectively, these data indicate that SH2B1 in the brain 
plays an essential role in the regulation of energy balance and suggest that SH2B1 is a 
physiologically relevant leptin signaling molecule. 
SH2B1 promotes leptin signaling 
SH2B1 has been shown to promote leptin signaling in cells by multiple 
mechanisms.  Leptin stimulates JAK2 autophosphorylation on Tyr813, and SH2B1 binds 
via its SH2 domain to phospho-Tyr813 to markedly enhance JAK2 activity (139).  
Importantly, the SH2 domain is both necessary and sufficient to promote JAK2 activity in 
response to leptin and to promote the activation of the leptin signaling pathways 
downstream of JAK2 (139).  Additionally, SH2B1 also directly binds to IRS-1 and IRS-2 
(55).  Leptin stimulates the formation of JAK2/SH2B1/IRS protein complexes, thereby 
promoting JAK2-mediated phosphorylation of IRS proteins and subsequent activation of 
the PI3K (55, 139, 185).  SH2B1 forms homodimers through its N-terminal dimerization 
domain (DD) (53, 169), which may also provide a platform to initiate the formation of 
JAK2/SH2B1/IRS protein complexes and/or to stabilize these complexes, in response to 
leptin.  Whether these mechanisms account for SH2B1-regulation of leptin action and 
control of energy balance in vivo is unknown.  In this Dissertation, I generated two 
transgenic mice models to further understand the mechanisms by which SH2B1 promotes 
energy balance in mice.  Specifically, I tested whether the SH2 domain of SH2B1 is 
necessary and sufficient for regulation of energy balance and body weight. 
SH2B1 is a candidate gene for human obesity 
Jamshidi and coworkers screened obese human populations for mutations in the 
SH2B1 gene (105).  They identified a single nucleotide polymorphism (SNP) within the 
human Sh2b1 loci that was strongly associated with serum leptin levels, total fat content, 
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and body weight in a European population of female twins (105).  Recently, two unbiased 
genome wide scans independently identified SNPs within the human Sh2b1 loci that were 
associated with indices of obesity (188, 221).  These findings implicate Sh2b1 as a 
candidate gene for obesity in man, particularly when coupled to the findings that SH2B1-
deficiency causes obesity in mice and overexpression of SH2B1 promotes leptin 
signaling. 
Additional physiological roles of SH2B1 
The obesity phenotype of SH2B1-KO mice, identification of SH2B1 as a leptin 
signaling molecule, and recent reports that the Sh2b1 locus is associated with leptin 
resistance and obesity in humans all provide strong evidence that one of the primary 
physiological functions of SH2B1 is to control energy balance, adiposity, and body 
weight.  Restoring SH2B1 expression specifically in neurons prevents energy imbalance, 
weight gain, and obesity in SH2B1-KO mice, indicating that central SH2B1 plays a 
critical role in the regulation of energy homeostasis in mice.  Moreover, by controlling 
energy balance and adiposity, SH2B1 in the brain indirectly promotes systemic insulin 
sensitivity to influence lipid and glucose metabolism.  However, SH2B1 is expressed in 
multiple tissues (skeletal muscle, white and brown adipose tissue, liver, pancreas, spleen, 
heart, and gonads) and may have multiple roles in mammalian physiology. 
Insulin controls blood glucose homeostasis.  SH2B1-KO mice develop severe 
insulin resistance and type 2 diabetes (56, 185).  Additionally, SH2B1 is expressed in 
insulin-target tissues and in the pancreas (56, 185).  In cells, SH2B1 promotes insulin, 
IGF-1 and GH signaling (56, 159).  This raises the intriguing hypothesis that SH2B1 in 
peripheral tissues and in the pancreas contributes to the regulation of glucose metabolism 
by promoting both insulin action and/or insulin production. 
Hormonal regulation of glucose metabolism 
Glucose is the major energy source for mammalian cells, and the precise 
regulation of blood glucose levels is required to sustain life.  Hypoglycemia (low blood 
glucose) impairs cellular metabolism and function, whereas hyperglycemia (elevated 
blood glucose) leads to glucose toxicity and irreversible tissue damage. 
The primary glucose sensor is the endocrine pancreas, which secretes two 
hormones that regulate glucose homeostasis: glucagon and insulin.  Glucagon is produced 
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and secreted by -cells in the islets of Langerhans.  Glucagon prevents prolonged 
hypoglycemia during fasting by promoting endogenous glucose production.  The liver, 
which is the primary target of glucagon, generates glucose from glycogen 
(glycogenolysis) and from de novo synthesis (gluconeogenesis) using gluconeogenic 
metabolites. 
Insulin is secreted by the -cells in the islets of Langerhans in response to 
elevations in blood glucose, which occurs acutely after feeding.  Insulin decreases blood 
glucose both by promoting glucose disposal and by counteracting the effects of glucagon 
in the liver.  Insulin promotes glucose disposal in skeletal muscle and adipose tissue by 
stimulating glucose uptake (via glucose transporter 4 (GLUT4)).  In skeletal muscle and 
liver, insulin promotes glycogen synthesis to facilitate glucose storage.  Insulin also 
suppresses the transcription of key gluconeogenic enzymes in the liver, thereby 
counteracting the effects of glucagon.  Thus, the physiological responses to insulin 
culminate in the rapid normalization of blood glucose levels following a meal; however, 
when these physiological responses are impaired or inadequate, blood glucose levels 
remain elevated (hyperglycemia) in the absorptive state.  This impaired or inadequate 
response to insulin is referred to as insulin resistance.  Insulin resistance in skeletal 
muscle and adipose tissue reduces the rate of glucose disposal, and hepatic insulin 
resistance results in increased hepatic glucose production. 
Peripheral insulin resistance contributes to the development of type II diabetes 
Insulin resistance precedes the development of a cluster of metabolic diseases, 
and is the primary defect underlying the development of type II diabetes (206, 207).  
More than 18 million Americans have Type II diabetes mellitus (or non-insulin 
dependent diabetes mellitus (NIDDM)), currently the sixth leading cause of death in the 
United States (75).  Insulin resistance has also been implicated in the development of 
cardiovascular disease, obesity, and polycystic ovarian syndrome.  Alarmingly, an 
estimated 70 to 80 million Americans may have some degree of insulin resistance (121), 
which increases the likelihood of developing these morbidities. 
In the prediabetic state, the insulin-producing cells of the pancreas (-cells) 
compensate for peripheral insulin resistance by secreting more insulin.  Thus, 
compensatory hyperinsulinemia is also a key feature and marker of peripheral insulin 
 12
resistance.  In most individuals, both hyperglycemia and hyperinsulinemia contribute to 
-cell dysfunction and failure (insulin insufficiency), which is the final step in the 
development of type II diabetes.  At that point, the intrinsic ability to regulate glucose 
homeostasis is lost, and administration of pharmacological levels of insulin (insulin 
therapy) is required to regulate blood glucose homeostasis. 
Mechanistically, systemic insulin resistance primarily arises secondary to 
impaired cellular insulin signaling in insulin-target tissues (206, 207).  Thus, 
understanding the cellular and molecular mechanisms by which insulin effectively 
regulates glucose homeostasis, how other hormones and cytokines influence cellular 
insulin sensitivity, and how these mechanisms are disrupted or impaired in insulin 
resistant individuals is not only an interesting pursuit to basic scientists, but also 
clinically relevant, as future treatments for multiple metabolic-related diseases may 
depend on these findings.  The key proteins that mediate insulin signal transduction have 
been identified and studied in both cell culture and animal models. 
Insulin activates the IRS/PI3K/Akt pathway to control glucose homeostasis 
The insulin receptor (IR) is a member of the tyrosine-kinase receptor family and 
is comprised of two extracellular -subunits and two membrane spanning -subunits 
linked by disulfide bonds.  Insulin binding to the -subunits induces a conformational 
change in the heterotetrameric receptor, activating the intrinsic tyrosine kinase within the 
 subunit.  The -subunit is then autophosphorylated on multiple tyrosine residues, which 
serve to both enhance tyrosine kinase activity and to create docking sites for intracellular 
signaling proteins. 
Signaling molecules that have either phosphotyrosine binding (PTB) or Src 2 
homology (SH2) domains bind to phosphotyrosines within the -subunit of the IR.  Upon 
binding, many of these proteins become substrates for the IR and are subsequently 
phosphorylated on multiple tyrosine residues by the activated kinase domain.  Shc, 
SH2B2(APS), and insulin receptor substrate (IRS) proteins are well characterized 
substrates for the insulin receptor.  Insulin stimulated tyrosine phosphorylation of these 
proteins initiates the activation of multiple intracellular signaling cascades. 
Shc phosphorylation triggers the activation of the Ras/Raf/MAPK pathway; this 
pathway is critical for insulin- and insulin-like growth factor 1 (IFG-1)-induced 
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mitogenesis (198).  In cultured adipocytes, insulin-stimulated SH2B2(APS) 
phosphorylation initiates the activation of the Cbl-B/TC10 pathway, which is sufficient 
for the translocation of GLUT4 vesicles to the plasma membrane (39, 141); however, the 
physiological significance of this pathway has not been firmly established as SH2B2 
knockout mice are surprisingly insulin sensitive (153).  Although the Shc/Ras/Raf/MAPK 
and SH2B2(APS)/Cbl-B/TC10 pathways are activated by insulin, the contribution of 
these pathways to the regulation of blood glucose by insulin in vivo are thought to be 
relatively insignificant.  Instead, the metabolic actions of insulin are primarily mediated 
through tyrosine phosphorylation of IRS proteins and subsequent activation of the 
PI3K/Akt pathway (44).  Activation of the IRS/PI3K/Akt pathway increases glucose 
transport into skeletal muscle and adipose tissue.  Additionally, activation of the 
IRS/PI3K/Akt pathway stimulates glycogen synthesis in muscle and liver, suppresses 
gluconeogenic enzyme transcription in the liver, and inhibits lipolysis in adipose tissue. 
The IRS/PI3K/Akt pathway is activated when the regulatory subunit of PI3K 
(p85) binds via its SH2 domains to phosphotyrosines within IRS proteins.  Binding of 
p85 to phosphorylated IRS proteins induces a conformational change in the holoenzyme 
to activate the catalytic subunit (p110).  PI3K phosphorylates membrane 
phosphatidylinositides to produce phosphatidylinositol 3,4,5-trisphosphate (PIP3).  PIP3 
accumulation recruits the serine/threonine-protein kinase Akt to the membrane (152), 
where it is phosphorylated on Thr308 and Ser473 by 3-phosphoinositide-dependent 
protein kinases (PDK1 and PDK2) (6, 236, 242).  Once activated by serine/threonine 
phosphorylation, Akt serves as the principal effector kinase in the PI3K-pathway, 
activating multiple cellular processes to promote glucose uptake and utilization and to 
suppress endogenous glucose production. 
Akt stimulates glucose uptake in skeletal muscle and adipose by activating the 
translocation and fusion of GLUT4 containing vesicles to the plasma membrane; this 
increases the rate of facilitated glucose diffusion into these tissues.  Additionally, Akt 
stimulates fatty acid, protein, and glycogen synthesis by regulating the activity and 
transcription of key enzymes involved in these processes; this further promotes cellular 
utilization of blood glucose.  Finally, Akt suppresses endogenous glucose production by 
inhibiting the transcriptional activity of the forkhead transcription factor FOXO1 in the 
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liver (167, 182, 187).  Because FOXO1 activates the transcription of rate-limiting 
gluconeogenic enzymes (phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-
phosphatase (G6P)) in liver, Akt-mediated inhibition of FOXO1 suppresses the rate of 
endogenous glucose production. 
Insulin-stimulated activation of the IRS/PI3K/Akt signaling pathway is vital to the 
regulation of glucose homeostasis in vivo.  In mice models of genetic- and diet-induced 
obesity, insulin-stimulated activation of PI3K-mediated signaling is diminished in the 
liver, skeletal muscle, and adipose tissue; these defects correlate with systemic insulin 
resistance and hyperglycemia (92, 150, 171, 254).  Genetic inactivation IRS-1 (108) or 
IRS-2 (126, 239), but not IRS-3 (142) or IRS-4 (68), results in peripheral insulin 
resistance in mice.  Homozygous deletion of either isoform of the catalytic subunit of 
PI3K (p110 or p110) is embryonic lethal (19, 20); however, mice heterozygous for 
both p110 isoforms (p110+/- and p110+/-) are insulin resistant (30).  Finally, deletion of 
Akt2 also disrupts glucose homeostasis (74), whereas Akt1- and Akt3-deficient mice 
have impaired growth but remain insulin sensitive (40, 57).  Although mice models have 
confirmed the essential role of PI3K-dependent signaling in the regulation of insulin 
sensitivity, the development of insulin resistance is a complex process and the underlying 
cellular mechanisms are not completely understood. 
Impaired IR kinase activity and/or reduced tyrosyl phosphorylation of IRS 
proteins are common cellular defects associated with the development of insulin 
resistance.  IR and IRS proteins are negatively regulated by various intracellular 
molecules, including PTP1B, Grb10, Grb14, SOCS1, SOCS3, JNK, PKC, S6K and 
IKK (1, 4, 6, 9-11, 13, 14, 25, 27-29, 33-35, 37, 44, 47).  The relative contribution of 
these negative regulators to the progression of insulin resistance has been extensively 
studied (2, 17, 46, 59, 78, 96, 114, 119, 196, 200, 205, 208, 222-224, 230, 235, 244, 255).  
For example, PTP1B, negatively regulate insulin action by dephosphorylating critical 
phosphotyrosines within the IR and IRS proteins (78, 197, 204); this serves to inactivate 
the receptor and to disrupt IRS-p85 association.  Elevated phosphatase activity may 
contribute to the pathogenesis of type II diabetes by inappropriately inhibiting insulin 
action.  In vivo, transgenic expression of PTP1B in skeletal muscle impairs insulin action 
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and disrupts glucose homeostasis (246), whereas Ptp1b-deficient mice are hypersensitive 
to insulin and have improved glycemic control (245). 
The proinflammatory environment that is associated with chronic obesity also 
drives insulin resistance.  Increased adiposity leads to elevated circulating levels of free 
fatty acids, adipose-derived cytokines, proinflammatory cytokines, and various other 
metabolites.  For example, levels of circulating tumor necrosis factor (TNF)- are 
significantly increased in obesity.  TNF- activates c-Jun NH2-terminal kinase (JNK) in 
skeletal muscle, liver, and white adipose tissue (1, 99).  JNK phosphorylates IRS-1 and 
IRS-2 on serine/threonine residues.  Unlike tyrosine phosphorylation, which promotes the 
activation of the PI3K/Akt-dependent signaling, serine/threonine phosphorylation of IRS-
1 or IRS-2 uncouples insulin signaling (1, 131).  Specifically, phosphorylation of IRS-1 
on serine 307 disrupts PTB domain function, inhibiting IRS-1 from binding to the IR.  
Serine phosphorylation also promotes ubiquitination and proteosome-mediated 
degradation of IRS proteins, limiting the pool of available substrate and hindering the 
ability of insulin to activate the PI3K/Akt pathway (233).  Recent data indicate that 
SH2B1 may be a positive regulator of insulin signaling in vivo (4, 5, 55, 56). 
Putative role of SH2B1 in the regulation of insulin signaling 
As discussed above, genetic deletion of SH2B1 results in severe insulin resistance 
and type 2 diabetes in mice (8).  However, SH2B1-KO mice are also severely obese due 
to leptin resistance (138, 185, 186), raising the possibility that insulin resistance may be 
secondary to obesity in SH2B1 null mice.  Preliminary data generated by our laboratory 
indicate that peripheral SH2B1 may be involved in the regulation of glucose homeostasis 
in vivo. 
First, the ability of exogenous insulin activate the IRS/PI3K/Akt pathway in 
skeletal muscle and liver is impaired in SH2B1-KO mice (56).  Second, preliminary 
hyperglycemic-euglycemic clamp studies indicate that insulin-stimulated glucose 
disposal and suppression of hepatic glucose production is impaired in SH2B1-KO mice 
(K. Cho and L. Rui, unpublished).  Finally, insulin fails to promote glucose uptake in 
adipocytes isolated from obese SH2B1-KO and lean TgSH2B1-KO male mice (M. Li, K. 
Cho., and L. Rui, unpublished).  Reconstitution of SH2B1 expression ex vivo improves 
insulin stimulated glucose uptake in SH2B1-deficient adipocytes (K. Cho and L. Rui, 
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unpublished), suggesting that SH2B1 cell autonomously promotes insulin action in 
adipocytes.  However, it is unclear whether peripheral SH2B1 directly regulates insulin 
sensitivity in insulin target tissues in vivo independent of body weight and increases in 
adiposity.  
Data generated from cell culture models also suggest a role for SH2B1 in insulin 
signaling.  Our laboratory previously reported that insulin signaling is enhanced by 
SH2B1 (8).  SH2B1 overexpression increases IR autophosphorylation and tyrosine 
phosphorylation of IRS-1 and IRS-2 in cultured cells (56, 137).  Similar observations 
were independently reported by two other groups (4, 249).  SH2B1 binds via its SH2 
domain to phospho-Tyr1158 in the activation loop of IR (121, 168).  Tyr1158 
phosphorylation occurs early in the activation of the insulin receptor kinase (234, 237, 
247), suggesting that binding of the SH2 domain of SH2B1 to phospho-Tyr1158 likely 
occurs early in the activation of the insulin signaling cascades.  This interaction may 
promote activation of IR by stabilizing the kinase domain of IR in an active 
conformation.  Consistent with these observations, SH2B1 complexes, which are 
immunoprecipitated from cell extracts, reportedly promote IR autophosphorylation by 
reducing the Km for ATP (249).  The same report also concluded that SH2B1 
dimerization was required for its stimulation of IR autophosphorylation, because 
treatment of cells with dimerization domain peptide mimetics inhibited IR 
autophosphorylation and downstream pathways (249).  Alternatively, SH2B1-IR 
interaction may facilitate IR binding to its substrates or prevent the binding of negative 
regulators, such as PTP1B and Grb7/10.  Additionally, SH2B1 directly binds to IRS-1 
and IRS-2 in vitro (55), further suggesting that SH2B1 may be involved in the activation 
of the IRS/PI3K/Akt pathway.   
In this dissertation, we examine the role of peripheral SH2B1 in the regulation of 
insulin action and glucose homeostasis.  We generated a mouse model in which 
recombinant SH2B1 is specifically expressed in the brain of SH2B1 null mice (TgKO) 
using transgenic approaches (186).  Since these mice have normal leptin sensitivity but 
lack SH2B1 in peripheral tissue, we were able to isolate the effects of SH2B1 deficiency 
on insulin signaling in skeletal muscle, liver, and adipose (Chapter 3).  Because the 
mechanism(s) by which SH2B1 promotes activation of the IRS/PI3K/Akt pathway are 
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not entirely cleat, we further examined the regulation of insulin signaling by SH2B1 
using cell culture and in vitro assays (Chapter 3). 
Putative role of SH2B1 in pancreatic  cell function 
Insulin resistance in peripheral tissues and insufficient insulin secretion (-cell 
dysfunction) contribute to the development of impaired glucose tolerance and 
hyperglycemia, hallmarks of type 2 diabetes.  Insulin is secreted by the -cells in the 
islets of Langerhans in response to elevations in blood glucose.  In the prediabetic state, 
-cells initially compensate for insulin resistance by increasing both insulin production 
and secretion (91, 109, 111, 181).  This compensatory mechanism, due to -cell 
proliferation (or islet hyperplasia), is the reason why insulin resistant individuals have 
both prolonged hyperglycemia and hyperinsulinemia (elevated insulin levels) following a 
glucose challenge.  However, the compensatory capacity of the -cell is limited and -
cells eventually fail to secrete adequate amounts of insulin to regulate blood glucose 
levels, and insulin therapy (administration of exogenous insulin) is needed to normalize 
blood glucose levels and prevent the development of diabetic complications 
(cardiovascular disease, neuropathies, renal failure, and blindness). 
Multiple growth factors, including insulin, insulin-like growth factor-1 (IGF-1), 
growth hormone (GH), and prolactin promote and support -cell function (47, 81, 104, 
118, 127, 129, 132, 166, 238, 239).  Many of the intracellular signaling pathways through 
which these growth factors modulate -cell function have been studied.  IGF-1 and 
insulin activate the IRS/PI3K/Akt pathway, which inhibits FOXO1 activity to promote 
Pdx1 expression (118, 127, 132, 166, 238, 239).  Pdx1 is a master transcriptional 
regulator in -cells that regulates the expression of genes necessary for -cell function, as 
well as those needed for proliferation and survival (3, 7, 8, 127).  Additionally, activation 
of the JAK2/STAT pathways by GH and prolactin promote -cell function and 
proliferation (47, 81, 104, 129).   
SH2B1 is expressed in the pancreas (56, 185).  SH2B1 is expressed at high levels 
- and -cells within the islet (S. Oka and L. Rui, unpublished data).  Additionally, 
SH2B1-KO mice are sensitive to the -cell toxin streptozotocin (STZ) (D. Ren, S. Oka, 
and L. Rui, unpublished data).  As discussed above, SH2B1 promotes the activation of 
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both the IRS/PI3K/Akt and JAK2/STAT pathways in insulin-, IGF-1-, and GH-treated 
cells and these growth factors support -cell survival and function (5, 25, 37, 40, 43).  
Therefore, SH2B1 may play a role in -cell function, survival, and/or proliferation.  
However, little is known about the physiological role of SH2B1 in the - or -cells.  In 
Chapter 4, we began to explore the role of SH2B1 in the pancreas in vivo, and provide 
evidence that SH2B1 promotes -cell function in genetically obese mice. 
Dissertation overview 
Leptin and insulin are key hormonal regulators of energy balance and glucose 
homeostasis.  SH2B1 is a PH- and SH2-domain containing adapter protein that promotes 
both leptin and insulin signaling in cells.  Disruption of Sh2b1 in mice causes obesity and 
diabetes, providing genetic evidence that SH2B1 is an essential regulator of energy 
balance and glucose homeostasis.  In this dissertation, the contribution of SH2B1 in 
brain, peripheral tissues, and islets to the regulation of body weight, energy balance, 
insulin sensitivity and glucose homeostasis were examined in vivo. 
The aims of this Dissertation were: 
1. To determine whether the SH2 domain of SH2B1 in neurons is required and/or 
sufficient for the ability of SH2B1 to regulate energy balance in mice (Chapter 2). 
2. To determine whether SH2B1 in peripheral tissues (skeletal muscle, liver, and 
white adipose tissue) directly promotes insulin action and regulates glucose homeostasis 
independent of central regulation of energy balance, body weight, and adiposity during 
diet-induced obesity (Chapter 3 and Chapter 4). 
3. To define the molecular mechanisms by which SH2B1 promotes insulin signaling 
(Chapter 3).  
4. To determine whether SH2B1 in the pancreas contributes to the regulation of 
glucose homeostasis by regulating -cell function (Chapter 4). 
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The SH2 Domain of SH2B1 in Neurons is Necessary but not Sufficient for 
Regulation of Body Weight and Glucose Homeostasis in Mice 
 
Abstract 
SH2B1 enhances leptin signaling in the hypothalamus to control energy balance 
and body weight in mice.  In cultured cells, the SH2 domain of SH2B1 alone is sufficient 
to promote JAK2 activation and leptin signaling.  Conversely, SH2 domain defective 
mutants of SH2B1 and SH2B2 function as dominant negatives and impair the ability of 
SH2B1 to enhance leptin signaling.  Here, we examined the function of the SH2 domain 
of SH2B1 in vivo.  Two transgenic mice models expressing either N-terminal truncated 
SH2B1 (amino acids 504-670) or a dominant negative form of SH2B1 (R555E) in 
neurons were generated to test whether the SH2 domain of neuronal SH2B1 is necessary 
and sufficient for the regulation of body weight.  N-terminal truncated SH2B1 (504) 
contained an intact SH2 domain and C-terminus of SH2B1, but lacked the dimerization 
domain, PH domain, and nuclear localization sequence (NLS).  Expression of 504 in 
neurons was not sufficient to prevent the development of obesity and obesity-associated 
metabolic disease in SH2B1-knockout (KO) mice, suggesting that multiple functional 
domains within SH2B1 are required for neuronal SH2B1 to control energy balance and 
body weight in mice.  Reconstitution of R555E in neurons also failed to prevent the 
development of obesity in SH2B1-KO mice.  By contrast, overexpression of R555E in 
the brain of wild type mice induced obesity and caused insulin resistance.  Collectively, 
these data indicate that a functional SH2 domain is necessary but not sufficient for 
regulation of energy balance and insulin sensitivity by neuronal SH2B1.  Moreover, these 
data suggest that dominant negative mutations within Sh2b1 could contribute to the 
pathogenesis of obesity. 
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Introduction 
Body weight is normally maintained within a narrow range by a sophisticated 
neuroendocrine system that controls energy (food) intake and energy expenditure.  The 
brain senses multiple signals of nutrient storage and availability and integrates those 
signals into appropriate physiological and behavioral responses to maintain energy 
homeostasis.  Obesity is caused by energy imbalance which occurs when long term 
energy (food) intake exceeds metabolic demand.  Excess energy is assimilated into 
triglyceride and stored in white adipose tissue, leading to increased adiposity and weight 
gain.  Leptin is secreted by adipocytes in direct proportion to white adipose mass, and 
conveys information about peripheral energy storage and availability to the 
hypothalamus.  Leptin suppresses food intake and promotes energy expenditure (8, 25, 
47, 56).  Paradoxically, serum leptin levels are elevated in obese individuals (14, 26, 35), 
suggesting that leptin resistance may underlie the pathogenesis of obesity.  Moreover, 
with the exception of rare monogenic forms of leptin deficiency, leptin treatment fails to 
induce weight loss in most cases of obesity (27).  Leptin resistance may be due to either 
defective leptin transport across the blood brain barrier (9, 18, 55) or impaired leptin 
signaling in hypothalamic neurons (3-5, 18, 40). 
Leptin signaling is mediated by the long form of the leptin receptor (LepRb), 
which is expressed in multiple neuronal subpopulations within the hypothalamus and 
other regions of the brain (19-21).  Leptin binding to LepRb activates the receptor-
associated tyrosine kinase, JAK2, which phosphorylates LepRb and downstream 
signaling molecules.  Signal transducer and activator of transcription 3 (STAT3) is 
activated by JAK2 in leptin-stimulated neurons (1, 2).  Disruption of the JAK2STAT3 
pathway, either by neuron-specific disruption of the STAT3 gene or genetic disruption of 
the STAT3 binding site in LepRb (Tyr1138Ser1138 knock-in mutation), results in 
obesity (15, 24).  JAK2 also activates PI3-kinase in leptin-stimulated neurons by 
recruiting and phosphorylating insulin receptor substrate-2 (IRS-2) (11, 16, 42, 45, 50).  
Systemic deletion of the IRS-2 gene or pharmacological inhibition of PI3-kinase activity 
results in obesity in mice models (34, 46, 57).  Activation of these two pathways may be 
negatively or positively regulated by cellular proteins that either inhibit (e.g. SOCS3 and 
PTP1B) or promote (e.g. SH2B1) JAK2 activity. 
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Leptin-stimulated activation of the JAK2STAT3 and the JAK2IRS-2/PI3-
kinase pathways in hypothalamic neurons is negatively regulated by SOCS3 and PTP1B 
(3, 5, 7, 13, 29, 38, 43, 61).  Expression of both SOCS3 and PTP1B is significantly 
increased in the hypothalamus in leptin resistant animals (22, 40, 41, 59), whereas 
neuron-specific deletion of SOCS3 or PTP1B improves leptin sensitivity (3, 38).  The 
JAK2-binding protein SH2B1 promotes leptin action in the hypothalamus (50, 51), and 
SH2B1 can restore leptin signaling in cells that overexpress PTP1B (50).  Thus, leptin 
sensitivity may be controlled by a balance between positive (e.g. SH2B1) and negative 
regulators (e.g. SOCS3 and PTP1B). 
SH2B1 is a PH and SH2 domain containing protein belonging to the SH2B family 
(10, 37).  SH2B1 promotes leptin-stimulated activation of both the JAK2STAT3 and 
the JAK2IRS-2/PI3-kinase pathways in cells and in the hypothalamus of mice (16, 31, 
33, 50).  Disruption of the Sh2b1 gene in mice results in hyperphagia, obesity, and 
obesity-associated metabolic disorders (32, 50, 51).  Recently, our laboratory reported 
that neuron-specific expression of recombinant SH2B1 in SH2B1-KO mice rescues 
obesity and prevents the development of obesity-related dyslipidemia and insulin 
resistance (51).  Additionally, overexpression of recombinant SH2B1 prevented diet-
induced obesity in transgenic mice (51).  Thus, SH2B1 in the brain controls energy 
balance and body weight.  
SH2B1 has been shown to enhance leptin signaling by multiple mechanisms.  
Leptin stimulates JAK2 autophosphorylation on Tyr813, and SH2B1 binds via its SH2 
domain to phospho-Tyr813 to markedly enhance JAK2 activity and promote the 
activation of the signaling pathways downstream of JAK2 (33, 44, 53).  Importantly, the 
SH2 domain alone is sufficient to promote JAK2 activity in leptin-treated cells (33).  
Additionally, SH2B1 also directly binds to IRS-1 and IRS-2 (16), and leptin stimulates 
the formation of JAK2/SH2B1/IRS-1 and JAK2/SH2B1/IRS-2 protein complexes, 
thereby specifically promoting JAK2-mediated phosphorylation of IRS proteins and 
activation of PI 3-kinase (16, 33, 50).  Interestingly, SH2 domain defective mutants of 
SH2B1 and SH2B2 impair the ability of SH2B1 to promote activation of the 
JAK2IRS-2/PI3-kinase pathway in cells (31, 33).  Because SH2B1 is a potent 
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endogenous leptin sensitizer, it is important to test these and other mechanisms in vivo in 
order to determine if SH2B1 has therapeutic potential for treatment of obesity. 
Here, we generated two transgenic mouse models to test whether the SH2 domain 
of SH2B1 in neurons is necessary and/or sufficient for SH2B1 to regulate body weight in 
vivo.  Neuron-specific expression of an N-terminal truncated form of SH2B1 that 
contained the entire SH2 domain and C-terminus (amino acids 504-670), but lacked other 
functional domains, did not correct energy imbalance in SH2B1-KO mice.  These data 
suggest that multiple domains within neuronal SH2B1 participate in the regulation of 
energy balance in vivo.  Neuron-specific expression of a dominant negative form of 
SH2B1 lacking a functional SH2 domain (SH2B1 R555E) also failed to prevent obesity 
or restore insulin sensitivity in SH2B1-KO mice.  However, neuron-specific expression 
of dominant negative SH2B1 R555E in wild type mice (TgR555E mice) induced obesity 
and caused insulin resistance.  These findings suggest that mutations in SH2B1 which 
alter SH2 domain function may contribute to leptin resistance and contribute to the 
development of obesity.  
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Materials and Methods 
Generation of transgenic and compound mutant mice.  SH2B1 knockout 
(KO), TgSH2B1, and KO/TgSH2B1 mice (C57BL/6 x SJL background) have been 
described (17, 51).  Transgenic mice that express either dominant negative (TgR555E) or 
truncated (Tg504) mutant forms of SH2B1 in neurons were generated for these 
studies.  A 4.9 kb transgene was generated by fusing cDNA encoding a Myc epitope 
tagged form of rat SH2B1 (R555E) downstream of the rat NSE (neuron-specific 
enolase) promoter/ GH (growth hormone) enhancer sequence described previously (30, 
51).  In parallel, a 3.7 kb transgene was generated by fusing cDNA encoding a Myc 
epitope tagged, N-terminal truncation of rat SH2B1 (amino acids 504-670) downstream 
of the NSE promoter/ GH enhancer.  Linear transgenic constructs were independently 
microinjected into F2 mouse oocytes (C57BL/6 x SJL) and surgically transferred to 
recipients by trained personnel at the University of Michigan Transgenic Animal Model 
Core facilities.  Founder mice were genotyped by PCR.  Ten TgR555E and eleven 
Tg504 founders were obtained.  Two independent lines of TgR555E mice (TgR555E205 
and TgR555E244) and two lines of Tg504 mice (Tg504301 and Tg504315), which 
expressed similar levels of recombinant SH2B1 R555E and SH2B1 504, 
respectively, were selected for analysis. 
Compound mutant mice were generated by crossing TgR555E or Tg504 mice 
with SH2B1-KO mice to generate KO/TgR555E or KO/Tg504 mice.  Male mice were 
used for all experiments.  Mice were housed on a 14-hour light/10-hour dark cycle in the 
Unit for Laboratory Animal Medicine (ULAM) at the University of Michigan.  Animal 
protocols were approved by the University Committee on the Use and Care of Animals 
(UCUCA). 
Growth and body composition.  Body weight was recorded weekly beginning at 
4 weeks of age.  Mice were briefly anesthetized (2-3% isoflurane), and body composition 
was determined by dual-energy X-ray absorptiometry (DEXA; PIXImus2 Dexa Scanner, 
GE Lunar Corporation).  Body fat (g) was normalized to body weight (g). 
Immunoprecipitation and immunoblotting.  Mice were fasted overnight (16-h) 
and anesthetized with Avertin (0.5 g tribromoethanol and 0.25 g tert-amyl alcohol in 39.5 
ml of water; 0.02 ml/g body weight).  Tissues were isolated, frozen in liquid nitrogen, 
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and stored at -80C until analysis.  Tissues were homogenized in lysis buffer (50 mM 
Tris [pH 7.5], 1% Nonidet P-40, 150 mM NaCl, 2 mM EGTA, 1 mM Na3VO4, 100 mM 
NaF, 10 mM Na4P2O7, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, and 10 
g/ml leupeptin).  Immunoprecipitation and immunoblotting were conducted as described 
previously (17).  Proteins were visualized using the Odyssey Infrared Imaging System 
(Li-Cor Biosciences) or ECL (Amersham).  SH2B1 antibodies have been described (17, 
51).  
Measurements of food intake and energy expenditure.  Mice were individually 
housed and food intake was recorded daily for 5-7 days.  Caloric value for the diet used 
was 4.6 kCal/g.  Metabolic rates were measured by indirect calorimetry (Oxymax Equal 
Flow system; Columbus Instruments).  Mice were individually housed and acclimated for 
24-h in metabolic cages.  After acclimation, exhaust air was sampled for a 24-h period.  
Samples were recorded for 1 minute at 27-minute intervals and O2 and CO2 content was 
determined.  Oxygen consumption (VO2) and carbon dioxide production (CO2) were 
normalized to lean body mass. 
Serum analysis.  Blood samples were collected from the tail vein.  Blood glucose 
concentrations were determined using a glucometer (Glucometer Elite XL; Bayer Corp., 
Tarrytown, NY).  Plasma insulin was determined using a rat insulin ELISA kit (Crystal 
Chem, Inc., Chicago, IL). 
Glucose and insulin tolerance tests.  For glucose tolerance tests (GTT), mice 
were fasted overnight (16-h) and D-glucose (2g/kg body weight) was injected 
intraperitoneally.  Blood glucose was measured 0, 15, 30, 60 and 120 min after glucose 
injection.  For insulin tolerance tests (ITT), mice were fasted for 6-h and human insulin 
(1 U/kg) was injected intraperitoneally.  Blood glucose was measured 0, 15, 30 and 60 
min after injection. 
Statistical Analysis.  Data are presented as means  SEM.  Differences between 




Generation of SH2B1-null mice expressing recombinant SH2B1 R555E and 
SH2B1 504 in the brain.  We previously reported that neuron-specific restoration of 
SH2B1 was sufficient to restore leptin sensitivity, prevent obesity, and reverse obesity-
associated metabolic diseases (hyperlipidemia and insulin resistance) in SH2B1-deficient 
(KO) mice (51).  To further define the role of the SH2 domain of SH2B1 in vivo, two 
mutant forms of rat SH2B1 were cloned into the same transgenic vector used to 
generate TgSH2B1 mice (51).  To generate TgR555E mice, cDNA encoding a Myc 
tagged SH2B1 mutant in which the SH2 domain is disrupted due to replacement of 
Arg555 with Glu (R555E) was used (Fig. 2.1A).  We have previously reported that this 
point mutation impairs the ability of SH2B1 to promote IRS-1 phosphorylation in 
leptin-treated cells (16, 17).  To generate Tg504 mice, cDNA encoding an N-terminal 
truncated mutant of rat SH2B1 (amino acids 504-670) was used (Fig. 2.1A).  This 
mutant contains an intact SH2 domain and C-terminus, but lacks the PH and dimerization 
(DD) domains.  In cells, 504 is sufficient to promote leptin signaling (16, 33).  Two 
independent lines were characterized for each SH2B1 mutant based on the criteria that 
the expression levels of recombinant R555E in TgR555E mice and recombinant 504 in 
Tg504 mice were similar to the expression of recombinant SH2B1 in TgSH2B1 mice 
(data not shown). 
To examine the effects of the mutant forms of recombinant SH2B1 in SH2B1 
deficient (KO) mice, TgR555E and Tg504 mice were crossed to KO mice to generate 
KO/TgR555E and KO/Tg504 compound mutant mice.  We first characterized the 
expression of recombinant R555E and 504 in the brains of compound mutant mice.  
Two forms of endogenous SH2B1 were detected in wild type (WT) mice, but only one 
form of SH2B1, corresponding to recombinant SH2B1, was detected in brain extract 
from KO/TgSH2B1 and KO/TgR555E mice.  Recombinant R555E was detected in both 
lines of KO/TgR555E mice (designated KO/TgR555E205 and KO/TgR555E244), and 
expression of R555E in both lines was similar to recombinant wild type SH2B1 in 
KO/TgSH2B1 mice (Fig. 2.1B).  The SH2B1 antiserum used to immunoprecipitate 
endogenous and recombinant forms of SH2B1 in brain samples from WT, KO/TgSH2B1, 
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and KO/R555E mice did not immunoprecipitate 504 in extracts from KO/Tg504 mice, 
presumably because the epitope is not present in recombinant 504 (data not shown).  
However, 504 was immunoprecipitated successfully using a second antibody raised 
against 504.  Expression of 504 in brain from two lines of KO/Tg504 mice 
(designated KO/Tg504301 and KO/Tg504315) was similar to recombinant SH2B1 in 
KO/TgSH2B1 mice (Fig. 2.1C).  For unknown reasons, the SH2B1 antibody against 
504 only recognized one form of endogenous SH2B1 in WT mice; nonetheless, this 
endogenous form co-migrated with recombinant SH2B1 from KO/TgSH2B1 mice (Fig. 
2.1C), and expression of 504 in KO/Tg504 mice brain was similar to the levels of 
recombinant and endogenous SH2B1 in KO/TgSH2B1 and WT mice, respectfully (Fig. 
2.1C). 
Neuron-specific restoration of SH2B1, but not R555E or 504 mutants, 
rescues obesity and corrects energy imbalance in SH2B1-KO mice.  To determine 
whether the SH2 domain of SH2B1 is required and sufficient to normalize body weight in 
SH2B1-deficient mice, body weight was monitored weekly in KO/TgR555E and 
KO/Tg504 male mice fed a standard diet, and compared to WT, KO, and KO/TgSH2B1 
male mice.  KO mice were significantly heavier than WT mice at 9 weeks of age and 
continued to gain weight rapidly thereafter (Fig. 2.2A).  KO mice were nearly 1.3 times 
heavier than WT mice at 16-weeks of age.  As expected, neuron-specific restoration of 
wild type SH2B1 prevented weight gain in KO/TgSH2B1 mice (Fig. 2.2A).  However, 
neuron-specific expression of SH2B1 R555E or SH2B1 504 failed to prevent weight 
gain in KO/TgR555E or KO/Tg504 mice, respectfully (Fig. 2.2A).  Body weight was 
similar in KO/TgR555E205, KO/TgR555E244, KO/Tg504301, and KO/Tg504315 male 
mice and comparable to KO mice (TgR555E205: 39.5 ± 2.2 g, n = 6; KO/TgR555E244: 
41.4 ± 3.0 g, n = 8; KO/Tg504301: 42.5 ± 2.6 g, n = 6; KO/Tg504315: 40.9 ± 2.5, n = 
10; KO: 41.9 ± 1.8 g, n = 10; 16-weeks).  Moreover, both the onset and rate of weight 
gain in KO/TgR555E and KO/Tg504 mice were similar to KO mice, indicating that 
neuron-specific expression of R555E and 504 does not alter the development of obesity 
in KO mice.  Whole body fat content in KO mice was more than 270% higher than WT 
mice (Fig. 2.2B).  Fat content was dramatically reduced in KO/TgSH2B1 mice (Fig. 
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2.2B), consistent with our previous findings (51).  By contrast, fat content was similar 
between KO, KO/TgR555E, and KO/Tg504 mice (Fig. 2.2B).  Lean mass and bone 
mineral content were also similar in WT, KO, KO/TgSH2B1, KO/TgR555E and 
KO/Tg504 mice (data not shown), indicating that differences in body weight are 
attributed to differences in fat mass. 
Increased adiposity may result from increased energy consumption, reduced 
energy expenditure, or a combination of both.  Therefore, food intake and energy 
expenditure were determined in KO/TgR555E and KO/Tg504 mice.  Average daily 
energy intake was more than 30% higher in KO, KO/TgR555E, and KO/Tg504 mice 
compared to WT and KO/TgSH2B1 mice at the same age (Fig. 2.2C).  By contrast, 
energy intake was similar between WT and KO/TgSH2B1 mice (Fig. 2.2C).  Previously, 
we reported that basal energy expenditure is increased in KO mice (50); however, energy 
intake still exceeds expenditure in KO mice, resulting in positive energy imbalance (50).  
In this study, twenty-four hour oxygen consumption and carbon dioxide production were 
increased to similar levels in KO, KO/TgR555E and KO/Tg504 mice (Fig. 2.2D-E).  By 
contrast, both oxygen consumption and carbon dioxide production in KO/TgSH2B1 mice 
were reduced to WT levels (Fig. 2.2D-E).  Collectively, these data indicate that neuron-
specific restoration of wild type SH2B1, but not mutant forms of SH2B1, can correct 
energy imbalance in SH2B1-deficient mice.  Thus, the SH2 domain is required but not 
sufficient for the regulation of energy balance and body weight in mice. 
Neuron-specific restoration of wild type SH2B1, but not R555E or 504, 
improves glucose metabolism and insulin sensitivity in SH2B1-knockout mice.  We 
previously proposed that SH2B1 in the brain improves insulin sensitivity by controlling 
adiposity and body weight (51).  Therefore, we examined glucose homeostasis in 
KO/TgR555E and KO/Tg504 mice to test whether expression of these mutant forms of 
SH2B1 in neurons altered insulin sensitivity and glucose metabolism. 
Fasting glucose levels in KO, KO/TgR555E, and KO/Tg504 mice were 1.8-, 
2.2-, and 1.7-times higher, respectfully, than WT mice at 17-19 weeks of age (Fig. 2.4A).  
Compared to KO mice, blood glucose levels were reduced in KO/TgSH2B1 mice, but 
hyperglycemia was not completely restored to WT levels (WT: 60.9 ± 4.5 mg/dl, n = 7; 
KO/TgSH2B1: 80.1 ± 4.4 mg/dl, n = 7; P<0.01; Fig. 4.3A).  Hyperglycemia was detected 
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as early as 10 weeks of age in fasted KO, KO/TgR555E, and KO/Tg504 mice and blood 
glucose levels were comparable between these three groups at this age (data not shown), 
suggesting that neuron-specific expression of R555E and 504 do not alter the onset or 
severity of hyperglycemia in KO mice.  Fasting insulin levels were 9 times higher in KO 
mice (Fig. 2.3B).  Neuron-specific restoration of SH2B1 corrected hyperinsulinemia in 
KO/TgSH2B1 mice whereas KO/TgR555E and KO/Tg504 mice remained 
hyperinsulinemic (Fig. 2.3B). 
To further examine peripheral insulin sensitivity, glucose and insulin tolerance 
tests were performed.  At 17-18 weeks of age, KO mice were severely glucose intolerant 
(Fig. 2.3C).  Like KO mice, glucose tolerance was also impaired in KO/TgR555E and 
KO/Tg504 mice, but improved in KO/TgSH2B1 mice (Fig. 2.3C).  The area under the 
glucose tolerance curve was similar for KO, KO/TgR555E, and KO/Tg504 mice (Fig. 
2.3C).  During insulin tolerance tests, exogenous insulin (1U/kg body weight) reduced 
blood glucose levels in WT and KO/TgSH2B1 mice, but not in KO, KO/TgR555E, or 
KO/Tg504 mice (Fig. 2.3D).  Blood glucose remained elevated in KO, KO/TgR555E, 
and KO/Tg504 mice, indicating that whole body insulin resistance was similar in these 
mice.  Together, these data indicate that neuron-specific restoration of wild type 
SH2B1, but not R555E or 504 mutants, improves glucose metabolism and insulin 
sensitivity in SH2B1-knockout mice.  Moreover, these data support our initial 
conclusions that SH2B1 in the brain promotes insulin sensitivity by regulating energy 
balance and adiposity.  
Dominant negative SH2B1 (R555E) in the brain alters energy balance and 
glucose homeostasis in wild type mice.  In cells, mutation of Arg 555 to Glu (R555E) in 
SH2B1 largely abolishes the ability of SH2B1 to promote leptin signaling (16, 33).  
Additionally, a naturally occurring mutant form of SH2B2, which lacks the SH2 
domain, but has intact dimerization and PH domains, can bind to SH2B1 and antagonize 
the ability of SH2B1 to promote leptin signaling (31).  This raises the possibility that 
dominant negative forms of SH2B family members may impair SH2B1 function in vivo. 
To test this, we examined the phenotype of TgR555E mice.  Expression of R555E 
in the brain of WT mice induced obesity (Fig. 2.4A).  Body weight in TgR555E and WT 
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mice was comparable from 3-12 weeks of age; however, after 13 weeks of age, body 
weight was significantly increased in TgR555E mice and TgR555E mice continued to 
gain weight thereafter (Fig. 2.4A).  Relative to KO mice, the onset of obesity in TgR555E 
mice was delayed (KO mice: 9 weeks; TgR555E: 13 weeks).  Moreover, TgR555E mice 
were not as heavy as KO mice (TgR555E205: 35.9 ± 2.9 g, n = 5; KO: 40.2 ± 2.0 g, n = 9; 
18 weeks of age), indicating that the severity of obesity differed between mice expressing 
dominant negative SH2B1 and mice lacking endogenous SH2B1.  Relative to wild type 
mice, whole body fat content was higher in TgR555E mice (TgR555E205: 13.2 ± 3.2 %, n 
= 6; WT: 7.2 ± 3.2 g, n = 5), but the difference did not reach significance (p=0.22).  
Taken together, these data indicate that over expression of dominant negative SH2B1 in 
neurons of wild type induces weight gain and increases adiposity. 
Food intake and energy expenditure was also determined in TgR555E mice.  Food 
intake was similar between TgR555E and WT mice (data not shown).  However, 
compared to WT mice, both oxygen consumption and carbon dioxide production 
increased in TgR555E mice (Figs. 2.4B-C).  This was also observed in KO mice, 
suggesting that loss of neuronal, rather than peripheral, SH2B1 some how alters energy 
consumption such that KO and TgR555E mice actually expend more energy than WT 
mice.   
 Glucose metabolism was also examined in TgR555E mice.  Compared to WT 
mice, fasting blood glucose levels were increased in TgR555E mice (Fig. 2.5A).  Glucose 
tolerance and insulin tolerance tests were performed to determine if neuron-specific 
overexpression of R555E altered insulin sensitivity.  The area under the glucose tolerance 
curve tended (P=0.12) to be larger for TgR555E mice than WT mice (Fig. 2.5B).  
However, insulin tolerance was impaired in TgR555E mice (Fig. 2.5C).  Taken together, 
these data indicate that overexpression of dominant negative SH2B1 in neurons of wild 
type mice impairs systemic insulin sensitivity and alters glucose metabolism. 
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Discussion 
Leptin resistance is a driving force in the development of obesity and obesity-
associated metabolic diseases, including hyperlipidemia and insulin resistance.  Two 
mechanisms for leptin resistance have been proposed.  First, impaired transport across the 
blood brain barrier appears to limit the ability of circulatory leptin to access target 
neurons in the hypothalamus and throughout the brain (9, 18, 55).  Second, leptin 
signaling in target neurons is attenuated by negative regulators such as SOCS3 and 
PTP1B (5-7, 23, 29, 43, 61).  Consistent with this, the expression of hypothalamic 
SOCS3 and PTP1B is increased in leptin resistant animals (4, 22, 40, 41, 48, 59).  We 
have reported that the JAK2-binding protein SH2B1 functions as an endogenous leptin 
sensitizer to control body weight by enhancing JAK2 activity and promoting leptin 
signaling (16, 32, 33, 50, 51).  In this study, we investigated the contribution of the SH2 
domain of SH2B1 to the regulation of energy balance and body weight in vivo. 
We report that restoration of an N-terminal truncated mutant of rat SH2B1 
(amino acids 504-670) in neurons of SH2B1-knockout mice (KO/Tg504) was not 
sufficient to prevent the development of obesity and obesity associated metabolic disease.  
Presumably, the inability of 504 to prevent obesity in KO/Tg504 mice was related to 
the inability of 504 to promote leptin action in vivo given that body weight, fat content, 
and energy imbalance in KO/Tg504 mice is nearly identical to leptin-resistant KO mice.  
Additional biochemical experiments are planned to confirm that leptin signaling is indeed 
impaired in KO/Tg504 mice.  
If leptin signaling is comprised in KO/Tg504 mice, as we predict, then the 
inability of the 504 transgene to restore energy balance would suggest that multiple 
functional domains within SH2B1 are required for leptin signaling in mice.  SH2B1 504 
contains an intact SH2 domain and C-terminus, but lacks the dimerization and PH 
domains (Fig. 2.1A).  These domains have been implicated in the regulation of cell 
signaling by SH2B1 and may participate in activation of the JAK2IRS-2/PI3-kinase 
pathway.  SH2B1 binds directly to IRS-1 and IRS-2, and a tertiary signaling complex 
comprised of JAK2/SH2B1/IRS-1 or JAK2/SH2B1/IRS-2 can be immunopurified from 
leptin-treated cells (16).  SH2B1 can bind via its PH domain to both kinase-inactive 
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JAK2 and a mutant form of IRS-1 lacking tyrosine residues (Y18F) (16, 54).  These 
phosphorylation-independent interactions may allow SH2B1 to scaffold latent signaling 
molecules in close proximity to LepRb in order to facilitate signaling upon leptin binding.  
Additionally, SH2B family members SH2B1 and SH2B2 form homo- and heterodimers 
via their respective dimerization domains (31, 49).  While dimerization of SH2B1 does 
not seem to be required for enhancing JAK2 activity in cells (53), homo- or 
heterodimerization of SH2B1 may facilitate the aggregation of signaling molecules into 
functional complexes around activated JAK2 (16).  Either of these two mechanisms 
might explain why neuron-specific restoration of 504 can not restore energy balance in 
KO/Tg504 mice. 
Alternatively, the inability of 504 to restore energy balance may be due to 
altered cellular distribution of 504 within neurons.  Altered cellular distribution of 
504, due to deletion of a functional domain, may sequester 504 away from the 
LepRb/JAK2 signaling complex.  Specifically, deletion of the PH domain may impair the 
ability of 504 to localize to the plasma membrane.  Recently, SH2B1 was shown to 
translocate between the cytoplasmic and nuclear compartments in NGF-treated PC12 
cells, a neuronal cell line (12, 36).  A nuclear localization sequence (NLS) in SH2B1 
between the dimerization and PH domains was identified (36).  The NLS is deleted in 
504 (Fig. 2.1A).  Thus, we can not exclude the possibility that disrupting cytoplasmic-
to-nuclear shuttling somehow contributes to the inability of 504 to restore energy 
balance in KO/Tg504 mice.  Regardless, our data suggest that 504 lacks at least one 
key functional domain which is necessary for the regulation of energy balance in mice. 
In cells, mutation of Arg 555 to Glu (R555E) in SH2B1 disrupts the SH2 domain 
and largely abolishes the ability of SH2B1 to promote leptin signaling (16, 33).  As 
predicted, reconstitution of SH2B1 R555E in neurons of KO/TgR555E mice failed to 
prevent the development of obesity, indicating that a functional SH2 domain is required 
for regulation of energy balance and body weight by SH2B1. 
Interestingly, overexpression of R555E in the brains of wild type mice induced 
obesity.  We also found that overexpression of R555E altered energy balance such that 
both oxygen consumption and carbon dioxide production were increased.  Oxygen 
consumption and carbon dioxide production are also elevated in KO mice, as 
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demonstrated in previous studies (50, 51).  This abnormal energy expenditure phenotype 
is reversed after neuron-specific restoration of SH2B1 in KO mice.  Collectively, these 
findings suggest that the mechanism that underlies abnormally elevated energy 
expenditure in both KO and TgR555E mice has a neuronal, rather than peripheral, origin. 
Mild obesity in TgR555E mice causes mild hyperglycemia and insulin resistance.  
However, insulin resistance does not appear to be as severe in TgR555E mice as in KO 
mice at the same age (17-18 wks).  The apparent difference in insulin sensitivity in 
TgR555E mice is likely due to the fact that endogenous SH2B1 is expressed in peripheral 
insulin-target tissues of these mice whereas the same tissues lack SH2B1 in KO mice.  
This is consistent with our recent report that peripheral SH2B1 enhances insulin signaling 
and contributes to the regulation of glucose homeostasis in mice (39). 
Interestingly, single nucleotide polymorphisms (SNPs) within the human Sh2b1 
loci are associated with leptin resistance and obesity (28, 52, 58, 60), supporting the 
concept that SH2B1 plays an essential role in the regulation of energy balance and body 
weight in man.  Although these SNPs have not been shown to be associated with altered 
SH2B1 function or expression, our findings suggest that mutations in the coding region 
of SH2B1 which alter SH2 domain function may be dominant and result in impaired 
leptin signaling and obesity.  In support of this concept, a naturally occurring mutant 
form of SH2B2, which lacks the SH2 domain, but has intact dimerization and PH 
domains, can bind to SH2B1 and antagonize the ability of SH2B1 to promote leptin 
signaling in cultured cells (31). 
In summary, restoration of SH2B1, but not the SH2 domain alone, in neurons 
corrects obesity in SH2B1-deficient mice.  Our findings suggest that multiple domains 
within SH2B1, possibly the DD, PH domain, or NLS, may be required for regulation of 
energy balance and body weight by SH2B1 in vivo.  Additionally, we report that 
overexpression of dominant negative SH2B1 (R555E) can induce obesity and mild 
insulin resistance in mice.  Collectively, these data indicate that neuron-specific 
expression of a functional SH2 domain of SH2B1 is not sufficient but is necessary for 
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Fig. 2.1.  Generation of SH2B1-null mice expressing recombinant SH2B1 R555E 
and SH2B1 504 in the brain.  (A)  Schematic representation of TgSH2B1, TgR555E, and 
Tg504.  The Myc epitope, dimerization (DD), PH, and SH2 domains are indicated.  (B)  Expression of 
SH2B1 in brain from KO, WT, KO/TgSH2B1 and two independent lines of KO/TgR555E mice.  SH2B1 
was immunoprecipitated (IP) with anti-SH2B1 (SH2B1) antibody and immunoblotted (IB) with SH2B1.  
(C)  Expression of SH2B1 in brain from KO, WT, KO/TgSH2B1 and two independent lines of KO/Tg504 






Fig. 2.2  Restoration of wild type SH2B1, but R555E or 504, in neurons prevents 
obesity and dyslipidemia in SH2B1-deficient mice.  (A)  Growth curve.  (B)  Whole body fat 
content was normalized to body weight (15-17 wks).  (C)  Food intake (13-14 wks).  (D-E)  Energy 
expenditure was determined by indirect calorimetry (15-17 wks).  (D)  Oxygen consumption and (E) 
carbon dioxide production was normalized to lean body mass.  The number of mice in each group is 















Fig. 2.3A-B.  Improved insulin sensitivity in KO/TgSH2B1, but not in KO/TgR555E 
or KO/Tg504 male mice.  (A)  Fasting (16-h) blood glucose levels and (B) plasma insulin levels 












Fig. 2.3C-D.  Improved insulin sensitivity in KO/TgSH2B1, but not in KO/TgR555E 
or KO/Tg504 male mice.  (C)  Glucose tolerance tests (GTT) performed on male mice (18-19 wks).  
Mice were fasted overnight (16-h) and D-glucose (2g/kg body weight) was administered by i.p. injection.  
Blood glucose levels were monitored 0, 15, 30, 60 and 120 min after injection.  (D)  Insulin tolerance tests 
(ITT) in male mice (18-19 wks).  Mice were fasted for 6-h and human insulin (1U/ kg body weight) was 
administered by i.p. injection.  Blood glucose was monitored 0, 15, 30 and 60 min after injection.  Values 
are expressed as a percentage of initial (time 0).  Area under the curve (AUC) was calculated for GTT and 
















Fig. 2.4  Expression of dominant negative SH2B1 in neurons disrupts energy 
homeostasis in WT mice.  (A)  Growth curves.  (B)  Oxygen consumption in male mice (15-17 wks).  
VO2 was normalized to lean body mass.  (C)  Carbon dioxide production in male mice (15-17 weeks).  




Fig. 2.5  Expression of dominant negative SH2B1 in neurons alters glucose 
metabolism and insulin sensitivity.  (A)  Fasting (16-h) blood glucose levels (17-18 wks).  (B)  
Glucose tolerance tests (GTT) performed on male mice (18-19 wks).  Mice were fasted overnight (16-h) 
and D-glucose (2g/kg body weight) was administered by i.p. injection.  Blood glucose levels were 
monitored 0, 15, 30, 60 and 120 min after injection.  (C)  Insulin tolerance tests (ITT) in male mice (18-19 
wks).  Mice were fasted for 6-h and human insulin (1U/kg body weight) was administered by i.p. injection.  
Blood glucose was monitored 0, 15, 30 and 60 min after injection.  Values are expressed as a percentage of 
initial (time 0).  Area under the curve (AUC) was calculated for GTT and ITT using the trapezoidal rule.  
The number of mice in each group is indicated in parenthesis.  *P < 0.05. 
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SH2B1 Enhances Insulin Sensitivity By Both Stimulating The Insulin Receptor And 
Inhibiting Tyrosine Dephosphorylation Of IRS Proteins 
 
Abstract 
SH2B1 is a SH2 domain-containing adaptor protein expressed in both the central 
nervous system and peripheral tissues.  Neuronal SH2B1 controls body weight; however, 
the function of peripheral SH2B1 remains unknown.  To address the role of peripheral 
SH2B1 in the regulation of insulin sensitivity and glucose metabolism, TgKO mice, 
which express SH2B1 in the brain but not in peripheral tissues, were fed a high fat diet 
(HFD).  Deletion of peripheral SH2B1 did not alter body weight or adiposity in HFD-fed 
TgKO mice.  However, deletion of SH2B1 in peripheral tissues exacerbated HFD-
induced hyperglycemia, hyperinsulinemia and glucose intolerance in TgKO mice.  
Insulin signaling was dramatically impaired in muscle, liver and adipose tissue in TgKO 
mice.  Deletion of SH2B1 impaired insulin signaling in primary hepatocytes, whereas 
SH2B1 overexpression stimulated tyrosine phosphorylation of insulin receptor substrates 
(IRS-1, IRS-2 and Shc).  The SH2 domain of SH2B1 was both required and sufficient to 
promote insulin signaling.  In vitro, recombinant SH2B1 promoted the catalytic activity 
of the insulin receptor, which required SH2B1 binding to Tyr1158 within the activated 
receptor.  Additionally, insulin stimulated the binding of SH2B1 to IRS-1 or IRS-2, and 
this physical interaction inhibited tyrosine dephosphorylation of IRS-1 or IRS-2 and 
increased the ability of IRS proteins to activate the PI 3-kinase pathway.  In conclusion, 
SH2B1 in peripheral tissues functions as an endogenous insulin sensitizer.  
Mechanistically, SH2B1 directly binds to the insulin receptor, IRS-1 and IRS-2, and 
enhances insulin sensitivity by both promoting receptor activity and by inhibiting 
tyrosine dephosphorylation of IRS proteins. 
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Introduction 
Insulin decreases blood glucose both by promoting glucose uptake into skeletal 
muscle and adipose tissue and by suppressing hepatic glucose production.  In type 2 
diabetes, the ability of insulin to reduce blood glucose is impaired (insulin resistance) due 
to a combination of genetic and environmental factors, resulting in hyperglycemia.  
Insulin resistance is not only the hallmark but also a determinant of type 2 diabetes.  
Insulin binds to and activates the insulin receptor (IR).  IR tyrosyl phosphorylates 
insulin receptor substrates (IRS-1, -2, -3 and -4).  IRS proteins, particularly IRS-1 and 
IRS-2, initiate and coordinate multiple downstream pathways, including the PI 3-
kinase/Akt pathway (38).  Genetic deletion of IRS-1, IRS-2 or Akt2 causes insulin 
resistance in mice, indicating that the IRS protein/PI 3-kinase/Akt2 pathway is required 
for regulation of glucose homeostasis by insulin (3, 5, 30, 43).  IR and IRS proteins are 
negatively regulated by various intracellular molecules, including PTP1B, Grb10, Grb14, 
SOCS1, SOCS3, JNK, PKC, S6K and IKK (1, 4, 6, 9-11, 13, 14, 25, 27-29, 33-35, 37, 
44, 47).  The relative contribution of these negative regulators to the progression of 
insulin resistance has been extensively studied (1, 4, 6, 9-11, 13, 14, 25, 27-29, 33-35, 37, 
40, 44, 47).  However, insulin signaling is likely to also be modulated by positive 
regulators.  In this study, we demonstrate that SH2B1 is a novel endogenous insulin 
sensitizer. 
SH2B1 is a member of the SH2B family of adapter proteins that also includes 
SH2B2 (APS) and SH2B3 (Lnk).  SH2B1 and SH2B2 are expressed in multiple tissues, 
including insulin target tissues (e.g. skeletal muscle, adipose tissue, liver and the brain); 
by contrast, SH2B3 expression is restricted to hematopoietic tissue (32, 36).  Structurally, 
SH2B family members have an N-terminal dimerization domain (DD), a central 
pleckstrin homology (PH) domain and a C-terminal Src homology 2 (SH2) domain.  The 
DD domain mediates homodimerization or heterodimerization between different SH2B 
proteins (21).  SH2B1 and SH2B2 bind via their SH2 domains to a variety of tyrosine 
phosphorylated proteins, including JAK2 and IR, in cultured cells (18).  Genetic deletion 
of SH2B1 results in marked leptin resistance, obesity, insulin resistance and type 2 
diabetes in mice, demonstrating that SH2B1 is required for the maintenance of normal 
body weight, insulin sensitivity and glucose metabolism (8, 17, 22, 23).  Surprisingly, 
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SH2B2 null mice have normal body weight and slightly improved insulin sensitivity (17, 
19), suggesting that SH2B1 and SH2B2 have distinct functions in vivo.  However, it 
remains unclear whether SH2B1 cell-autonomously regulates insulin sensitivity in 
peripheral insulin target tissues because systemic deletion of SH2B1 causes obesity, 
which may cause insulin resistance in SH2B1 null mice. 
We generated a mouse model in which recombinant SH2B1 is specifically 
expressed in the brain of SH2B1 null mice (TgKO) using transgenic approaches (23).  
Neuron-specific restoration of SH2B1 corrects both leptin resistance and obesity, 
suggesting that neuronal SH2B1 regulates energy balance and body weight by enhancing 
leptin sensitivity (23).  Consistent with these conclusions, polymorphisms in the SH2B1 
loci are linked to leptin resistance and obesity in humans (24, 31, 42).  In this work, we 
demonstrate that deletion of SH2B1 in peripheral tissues impairs insulin sensitivity 
independent of obesity in TgKO mice.  Moreover, we demonstrate that SH2B1 directly 
promotes insulin responses by stimulating IR catalytic activity and by protecting IRS 
proteins from tyrosine dephosphorylation. 
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Materials and Methods 
Animal Studies.  SH2B1 KO and TgKO mice have been described previously (8, 
23), and were backcrossed for 6 generations onto a C57BL/6 genetic background.  Mice 
were housed on a 12-h light/dark cycle in the Unit for Laboratory Animal Medicine at the 
University of Michigan, and fed either normal rodent chow (9% fat; Lab Diet) or HFD 
(45% fat; Research Diets) ad libitum with free access to water.  Fat content was measured 
by dual energy x-ray absorptiometry (Norland Medical System).  Blood glucose levels 
were determined using glucometers (Bayer Corp).  Plasma insulin was measured using a 
rat insulin ELISA kit (Crystal Chem).  Glucose tolerance tests (GTT) (2 g D-glucose/kg 
of body weight) and insulin tolerance tests (ITT) (1 IU/kg of body weight; Eli Lilly) were 
conducted as previously described (8, 22, 23).  To analyze insulin signaling, mice (fasted 
16-h) were anesthetized with Averin (0.5 g of tribromoethanol and 0.25 g or tert-amyl 
alcohol in 39.5 ml of water; 0.02 ml/g of body weight), and treated with phosphate 
buffered saline (PBS) or human insulin (3 U per mouse; Eli Lilly) via inferior vena cava 
injection.  Five minutes after injection, gastrocnemius muscles, liver and epididymal fat 
pads were dissected, frozen in liquid nitrogen and stored at -80ºC.  Tissues were 
homogenized in ice cold lysis buffer (50 mM Tris HCl, pH 7.5, 1.0% NP-40, 150 mM 
NaCl, 2 mM EGTA, 1 mM Na3VO4, 100 mM NaF, 10 mM Na4P2O7, 1 mM PMSF, 10 
g/ml aprotinin, 10 g/ml leupeptin) and extracts were immunoblotted or 
immunoprecipitated with indicated antibodies.  Animal protocols were approved by the 
University Committee on Use and Care of Animals. 
Cell lines and Transfection.  COS-7 and HEK293 cells were grown in DMEM 
supplemented with 5% bovine serum and transfected with indicated plasmids using 
Lipofectamine 2000 (Invitrogen).  Chinese hamster ovary (CHOIR and CHOIR/IRS-1) cells 
were cultured in Ham’s F-12 media supplemented with 8% FBS.  Cells were deprived of 
serum for 16-h in DMEM (COS-7 and HEK293) or F-12 (CHO) containing 0.6% BSA 
before being treated.  Primary liver cells were isolated from male mice (8 weeks) by 
perfusion of the liver with type II collagenase (Worthington Biochem), and plated on 
collagen coated plates in M199 containing 10% FBS, 100 units/ml penicillin and 100 
µg/ml streptomycin.  After 2-h, primary cells were rinsed in PBS and cultured for an 
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additional 16-h in Williams’ Medium E (Sigma) supplemented with 0.6% BSA, 100 
units/ml penicillin and 100 µg/ml streptomycin. 
Immunoprecipitation and Immunoblotting.  Immunoprecipitation and 
immunoblotting were conducted as described previously (7, 8).  Proteins were visualized 
using the Odyssey Infrared Imaging System (Li-Cor Biosciences) or ECL (Amersham), 
and quantified using Odyssey 1.2 software (Li-Cor). Actin, phospho-Akt (Thr308), Akt, 
insulin receptor , Myc, Shc and tubulin antibodies were from Santa Cruz.  The 
phosphotyrosine-specific antibody was from Upstate.  The AS160 antibody was from 
Millipore and phospho Akt substrate (PAS) antibody was from Cell Signaling.  Phospho- 
Akt (Ser473) was from BioSource.  SH2B1 and IRS-1 antibodies have been described (7, 
25). 
Insulin Receptor Kinase Assay.  Cells were serum-deprived for 16-h, treated 
with insulin and solubilized in kinase lysis buffer (50 mM Tris HCl [pH 7.5], 0.1% Triton 
X-100, 150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, 1 mM PMSF, 10 g/ml aprotinin, 
10 g/ml leupeptin).  The insulin receptor (IR) was precipitated with wheat germ 
agglutinin (WGA)-conjugated agarose beads, washed three times in wash buffer (50 mM 
Tris HCl [pH 7.5], 0.5 M NaCl, 0.1% Triton X-100) and twice in kinase reaction buffer 
(20 mM Hepes [pH 7.6], 0.1% Triton X-100, 5 mM MgCl2, 100 M Na3VO4).  WGA-
immobilized proteins were preincubated in kinase reaction buffer supplemented with 
soluble glutathione-S-tranferase (GST) protein alone, GST-SH2B1 or GST-SH2 fusion 
proteins at 37C.  GST-IRS-1 (5-10 g) and ATP (50 M) were added to initiate kinase 
reactions at 37C.  Reactions were stopped by adding SDS-PAGE loading buffer and 
reaction mixtures were boiled immediately.  Proteins were separated by SDS-PAGE and 
immunoblotted with indicated antibodies. 
Dephosphorylation Assays.  Immunopurified proteins were washed in lysis 
buffer and preincubated with GST-SH2B1 or GST (2 g) in phosphatase reaction buffer 
(50 mM Tris-HCl [pH 8.2], 100 nM NaCl, 10 mM MgCl2, 1 mM DTT) for 15 min at 
room temperature with constant mixing.  Alkaline phosphatase (New England Biolabs) 
was added at the indicated concentration, and the mixtures were incubated an additional 
30 min at room temperature.  Reactions were stopped by adding SDS-PAGE loading 
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buffer and mixtures were boiled immediately.  Proteins were separated by SDS-PAGE 
and immunoblotted with indicated antibodies. 
Statistical Analysis.  Data are presented as means  SEM.  Differences between 




Loss of peripheral SH2B1 predisposes mice to high fat diet (HFD)-induced 
insulin resistance.  We previously generated SH2B1 transgenic (Tg) mice in which the 
expression of recombinant SH2B1 is controlled by the neuron-specific enolase promoter 
(23).  Tg mice were crossed with SH2B1 knockout (KO) mice to generate SH2B1 
transgenic/knockout compound mutant (TgKO) mice.  In TgKO mice, recombinant 
SH2B1 is expressed in brain but not in other tissues, including liver, muscle and adipose 
tissue (23).  Neuron-specific restoration of SH2B1 in TgKO mice fully corrected leptin 
resistance and obesity, and largely rescued the hyperglycemia and insulin resistance 
observed in SH2B1 null mice, indicating that neuronal SH2B1 indirectly regulates insulin 
sensitivity and glucose metabolism by controlling adiposity (23). 
To determine whether loss of peripheral SH2B1 exacerbates dietary fat-induced 
insulin resistance, TgKO and wild type littermates (7 weeks) were fed HFD.  Body 
weight and adiposity were similar between wild type and TgKO mice fed HFD (Figs. 
3.1A-B).  However, fasting (16-h) blood glucose levels were 1.3-fold higher in TgKO 
mice than in wild type mice fed HFD for 16 weeks (Fig. 3.1C).  Fasting plasma insulin 
levels were 2-fold higher in TgKO mice than in wild type mice (Fig. 3.1D).  To examine 
insulin sensitivity, glucose and insulin tolerance tests (GTT and ITT) were performed.  
Blood glucose levels were 23-26% higher in TgKO mice than wild type mice 15 and 30 
minutes after injection of D-glucose (Fig. 3.1E).  Exogenous insulin markedly reduced 
blood glucose in wild type but not in TgKO mice during ITT (Fig. 3.1F).  These results 
indicate that loss of peripheral SH2B1 exacerbates HFD-induced insulin resistance, 
hyperglycemia, and glucose intolerance independent of obesity. 
Loss of peripheral SH2B1 impairs insulin signaling in muscle, liver and 
adipose tissue in HFD-fed mice.  To examine insulin signaling in skeletal muscle, liver 
and epididymal fat, mice (7 weeks) were fed HFD for 16 weeks and treated with insulin 
or PBS vehicle.  Insulin markedly stimulated tyrosine phosphorylation of IRS-1 as well 
as IRS-1 association with p85, the regulatory subunit of the PI 3-kinase, in skeletal 
muscle of wild type mice (Fig. 3.2A).  Both IRS-1 phosphorylation and IRS-1-p85 
association were markedly reduced in TgKO muscle (Fig. 3.2A).  Loss of peripheral 
SH2B1 also decreased insulin receptor autophosphorylation and impaired the ability of 
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insulin to stimulate Akt phosphorylation on Thr308 and Ser473 in TgKO muscle (Fig. 
3.2A).  Insulin-stimulated IRS-1 and Akt Thr308 phosphorylation were reduced by 44% 
and 52%, respectfully, in TgKO muscle (Fig. 3.2B). 
Insulin signaling was also examined in liver and white adipose tissue (WAT) from 
HFD-fed mice.  Relative to wild type mice, basal IRS-1 phosphorylation was increased in 
both liver and white adipose tissue (WAT) in TgKO mice; insulin stimulated IRS-1 
phosphorylation in these tissues from wild type but not TgKO mice (Figs. 3.2C and 
3.2E).  Akt phosphorylation (Ser473) was also reduced in liver (Fig. 3.2D) and WAT (not 
shown) in TgKO mice.  AS160, a Rab-GAP, is an Akt-substrate involved in GLUT4 
vesicle trafficking in adipocytes (12, 26).  To measure AS160 phosphorylation, WAT 
extracts were immunoprecipitated with anti-phospho-Ser/Thr Akt substrate antibody and 
immunoblotted with anti-AS160 antibody.  Similar to IRS-1, basal AS160 
phosphorylation was increased in adipose tissue from TgKO mice (Fig. 3.2F); however, 
insulin failed to further stimulate AS160 phosphorylation (Fig. 3.2F).  Together, these 
data indicate that peripheral SH2B1 increases insulin sensitivity in mice by promoting 
insulin signaling, including the activation of the IRS protein/PI 3-kinase/Akt pathway, in 
muscle, liver and white adipose tissue. 
SH2B1 cell-autonomously promotes insulin signaling via its SH2 domain.  To 
determine whether endogenous SH2B1 directly enhances insulin signaling, primary 
hepatocyte cultures were prepared from wild type and SH2B1 KO littermates, and treated 
with insulin.  SH2B1 was detected in wild type but not in KO hepatocytes as expected 
(Fig. 3.3A).  Insulin stimulated tyrosine phosphorylation of IR and IRS-1, IRS-1 
association with p85, and phosphorylation of Akt in wild type hepatocytes; however, IR 
autophosphorylation, IRS-1 phosphorylation, IRS-1 association with p85, and Akt 
phosphorylation were all reduced in KO hepatocytes (Fig. 3.3A).  Interestingly, SH2B1 
deficiency impaired IRS-1 phosphorylation to a greater extent than IR 
autophosphorylation.  In HEK293 cells, overexpression of SH2B1 markedly increased 
insulin-stimulated tyrosine phosphorylation of IRS-1; in contrast, a SH2B1 mutant in 
which the SH2 domain is disrupted due to replacement of Arg555 with Glu (R555E) 
functioned as a dominant negative to inhibit IRS-1 phosphorylation (Fig. 3.3B).  To 
further assess the role of the SH2 domain of SH2B1, IRS-1 and IR were coexpressed with 
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N504, an N-terminal truncated form of rat SH2B1β (amino acids 504-670) that 
contained the entire SH2 domain and a minimal number of adjacent amino acids.  N504 
also promoted IRS-1 phosphorylation in insulin-treated cells (Fig. 3.3C).  These data 
suggest that the SH2 domain of SH2B1 is not only required but also sufficient to promote 
IR-mediated phosphorylation of IRS-1. 
To determine whether SH2B1 also promotes phosphorylation of other IR 
substrates, Shc was coexpressed with SH2B1 or N504.  SH2B1 and N504 enhanced 
insulin stimulation of Shc phosphorylation to similar levels (Fig. 3.3D).  By contrast, 
SH2B1 stimulated IRS-1 phosphorylation to a higher level than did N504 (Fig. 3.3C), 
suggesting that SH2B1 promotes phosphorylation of IRS-1 and Shc by different 
mechanisms. 
SH2B1 stimulates IR catalytic activity through the binding of its SH2 domain 
to Tyr1158 in IR.  SH2B1 directly binds via its SH2 domain to Tyr1158 within the 
activation loop of IR (15, 20).  To test whether this interaction modulates IR activation, 
CHOIR cells, which stably express IR, were treated with insulin, and active IR was 
purified using wheat germ agglutinin (WGA)-conjugated agarose beads (39).  IR was 
then pre-incubated with purified GST-SH2B1 fusion protein, and subsequently subjected 
to in vitro kinase assays using GST-IRS-1 fusion protein as substrate.  Tyrosine 
phosphorylation of GST-IRS-1 was measured by immunoblotting with anti-phospho-
tyrosine antibodies.  GST-SH2B1, but not GST alone, dose-dependently stimulated IR 
kinase activity as indicated by increased phosphorylation of GST-IRS-1 (Fig. 3.4A).  In 
similar experiments, a GST-SH2 fusion protein prepared by fusing the SH2 domain 
(amino acids 524-670 of SH2B1) to GST was preincubated with WGA-purified IR in 
vitro kinase assays.  The SH2 domain of SH2B1 was sufficient to enhance IR catalytic 
activity, stimulating IRS-1 phosphorylation by ~66 % (Fig. 3.4B).  Additionally, the SH2 
domain of SH2B1 also promoted the catalytic activity of IR immunopurified with an anti-
phospho-tyrosine antibody, increasing IRS-1 substrate phosphorylation by ~79 % (Fig. 
3.4C). 
To determine whether Tyr1158 in IR is involved in SH2B1 stimulation of IR 
activity, Tyr1158 was replaced with Phe (Y1158F). COS-7 cells were transiently 
transfected with IR or Y1158F and treated with insulin.  Insulin stimulated 
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autophosphorylation of both IR and Y1158F, but Y1158F autophosphorylation was 
reduced (Fig. 3.4D).  Y1158F phosphorylated IRS-1 in response to insulin (data not 
shown), indicating that Y1158F retains the ability to be activated and to phosphorylate its 
substrates.  IR and Y1158F were purified using WGA-beads, preincubated with GST-
SH2B1, and subjected to in vitro kinase assays.  SH2B1 stimulated IR kinase activity by 
~5 fold; however, SH2B1 was unable to stimulate Y1158F catalytic activity (Fig. 3.4E).  
Taken together, these data suggest that the physical interaction between the SH2 domain 
of SH2B1 and Tyr1158 in IR is required and sufficient for stimulation of IR catalytic 
activity. 
SH2B1 protects IRS proteins against tyrosine dephosphorylation.  SH2B1 
directly binds to IRS-1 and IRS-2 in vitro (7), and insulin stimulated 
coimmunoprecipitation of SH2B1 with IRS-1 in cells (Fig. 3.5A).  To determine whether 
this physical interaction inhibits IRS-1 dephosphorylation by phosphatases, CHOIR/IRS-1 
cells, which stably express IR and IRS-1, were stimulated with insulin to promote 
tyrosine phosphorylation of IRS-1.  Phosphorylated IRS-1 was immunopurified, 
preincubated with GST or GST-SH2B1, and subjected to in vitro dephosphorylation 
assays.  IRS-1 bound to GST-SH2B1 but not to GST (data not shown).  Alkaline 
phosphatase dose-dependently dephosphorylated IRS-1 on tyrosines in the GST-
pretreated samples; in contrast, alkaline phosphatase was unable to dephosphorylate 
SH2B1-bound IRS-1 (Fig. 3.5B).  Insulin also promoted the association of SH2B1 with 
IRS-2, and SH2B1 similarly inhibited tyrosine dephosphorylation of IRS-2 (data not 
shown). 
To determine whether SH2B1 inhibits IRS-1 dephosphorylation in cells, IRS-1 
was coexpressed with PTP1B (a protein tyrosine phosphatase) in the absence or presence 
of SH2B1.  PTP1B dephosphorylated IRS-1, and SH2B1 dose-dependently attenuated the 
ability of PTP1B to dephosphorylate IRS-1 (Fig. 3.5C).  To determine whether SH2B1 is 
able to promote IRS-1 phosphorylation without stimulating IR kinase activity, Y1158F 
was coexpressed with SH2B1.  Although SH2B1 was unable to stimulate Y1158F kinase 
activity (Fig. 3.4E), SH2B1 still markedly enhanced tyrosine phosphorylation of IRS-1 in 
Y1158F-expressing cells (Fig. 3.5D).  Thus, SH2B1 is likely to augment Y1158F-
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mediated phosphorylation of IRS-1 by inhibiting IRS-1 dephosphorylation by 
endogenous protein phosphatase(s). 
To determine whether the SH2B1-IRS interaction sterically inhibits the binding of 
IRS proteins to PI 3-kinase, IRS-1 and Y1158F were coexpressed with or without SH2B1 
in HEK293 cells, and IRS-1-p85 association was examined by co-immunoprecipitation 
assays.  Insulin stimulated coimmunoprecipitation of IRS-1 with p85; importantly, 
SH2B1 markedly enhanced insulin-stimulated p85 binding to IRS-1 (Fig. 3.5E).  These 
data indicate that the SH2B1-IRS interaction does not interfere with IRS-PI 3-kinase 
interaction, but rather increases the IRS-PI 3-kinase association by inhibiting IRS 
dephosphorylation.  Consistent with these observations, SH2B1 also enhanced insulin-
stimulated, Y1158F-mediated Akt phosphorylation (Fig. 3.5F).  Collectively, these data 
suggest that, in addition to enhancing IR catalytic activity via binding to Tyr1158, 
SH2B1 also promotes activation of the IRS protein/PI 3-kinase/Akt pathway by 
inhibiting IRS dephosphorylation. 
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Discussion 
Insulin resistance is the primary risk factor for various metabolic diseases, 
including type 2 diabetes, non-alcoholic fatty liver disease, dyslipidemia and 
cardiovascular disease.  The molecular mechanisms underlying insulin resistance are 
extremely complex and not completely understood.  It is commonly accepted that 
impairments in insulin signal transduction play a key role in the development of insulin 
resistance.  We previously observed that insulin signaling is enhanced by SH2B1 (8).  
SH2B1 overexpression increases IR autophosphorylation and tyrosine phosphorylation of 
IRS-1 and IRS-2 in cultured cells (8, 16).  Similar observations were independently 
reported by two other groups (2, 46).  Additionally, we showed that genetic deletion of 
SH2B1 results in severe insulin resistance and type 2 diabetes in mice (8).  However, 
SH2B1 null mice are also severely obese due to leptin resistance (17, 22, 23), raising the 
possibility that insulin resistance may be secondary to obesity in SH2B1 null mice.  
Therefore, it was unclear whether peripheral SH2B1 directly regulates insulin sensitivity 
in insulin target tissues in vivo. 
We generated TgKO mice that express SH2B1 only in the brain but not in 
peripheral tissues (e.g. liver, muscle and adipose tissue).  Body weight was similar 
between TgKO and wild type littermates fed either normal chow or HFD, consistent with 
our previous conclusion that neuronal SH2B1 controls energy balance and body weight 
by promoting leptin sensitivity (23).  In the current study, we demonstrated that loss of 
peripheral SH2B1 markedly impaired insulin sensitivity independent of body weight.  
TgKO mice developed hyperglycemia, hyperinsulinemia and glucose intolerance to a 
greater extent than wild type littermates fed HFD.  The ability of exogenous insulin to 
reduce blood glucose and to stimulate IR autophosphorylation and phosphorylation of 
IRS proteins and Akt in muscle, liver, and adipose tissue was significantly reduced in 
TgKO mice.  These results suggest that peripheral SH2B1 serves as an endogenous 
insulin sensitizer.  Insulin signaling has been shown to be attenuated by multiple 
intracellular signaling molecules (e.g. PTP1B, Grb10, Grb14, SOCS1, SOCS3, JNK, 
PKC, S6K and IKK) which contribute to the development of insulin resistance (1, 4, 6, 
9-11, 13, 14, 25, 27-29, 33-35, 37, 40, 44, 47).  Our data suggest that insulin sensitivity is 
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controlled by a balance between these negative regulators and SH2B1 in insulin target 
cells. 
SH2B1 promotes insulin signaling by stimulating IR catalytic activity.  SH2B1 
binds via its SH2 domain to phospho-Tyr1158 in the activation loop of IR (15, 20).  We 
showed that bacteria-derived SH2B1 markedly increased the ability of purified IR to 
tyrosyl phosphorylate IRS-1 in vitro.  In contrast, SH2B1 was unable to stimulate the 
catalytic activity of Y1158F, an IR mutant lacking the binding site for SH2B1.  In cells, 
SH2B1 overexpression promotes IR autophosphorylation as well as IR phosphorylation 
of its substrates (e.g. IRS-1, IRS-2 and Shc).  Conversely, deletion of endogenous SH2B1 
impaired insulin stimulation of IR autophosphorylation and IRS-1 phosphorylation in 
primary hepatocyte cultures.  Consistent with these observations, SH2B1 complexes, 
which are immunoprecipitated from cell extracts, reportedly promote IR 
autophosphorylation by reducing the Km for ATP (46).  The same report also concluded 
that SH2B1 dimerization was required for its stimulation of IR autophosphorylation, 
because treatment of cells with dimerization domain peptide mimetics inhibited IR 
autophosphorylation and downstream pathways (46).  However, the report did not 
provide evidence showing that the mimetics disrupted SH2B1 dimerization.  In contrast, 
we observed that the SH2 domain alone was sufficient to stimulate IR catalytic activity in 
vitro.  Moreover, N504, a N-terminal truncated SH2B1 containing the intact SH2 
domain but completely lacking both dimerization and PH domains, still markedly 
enhanced insulin-stimulated tyrosine phosphorylation of both IRS-1 and Shc.  
Conversely, R555E, a SH2B1 mutant with a defective SH2 domain, inhibited insulin 
signaling as a dominant negative mutant.  These data indicate that the SH2 domain of 
SH2B1 is both required and sufficient to stimulate IR kinase activity.  Because Tyr1158 
phosphorylation occurs early in the activation of the insulin receptor kinase (39, 41, 45), 
binding of the SH2 domain of SH2B1 to phospho-Tyr1158 may stabilize IR in an active 
conformation.  Alternatively, SH2B1-IR interaction may facilitate IR binding to its 
substrates. 
Insulin stimulated the binding of SH2B1 to IRS-1 or IRS-2.  Importantly, SH2B1 
directly inhibited tyrosine dephosphorylation of IRS-1 and IRS-2 by recombinant 
phosphatase in vitro and by PTP1B in cultured cells.  Although unable to stimulate 
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Y1158F catalytic activity, SH2B1 still enhanced Y1158F-mediated phosphorylation of 
IRS-1 in cultured cells, presumably by inhibiting IRS-1 dephosphorylation by 
endogenous tyrosine phosphatase(s).  Consistent with these observations, deletion of 
endogenous SH2B1 impaired tyrosine phosphorylation of IRS-1 to a greater extent than 
IR autophosphorylation in primary hepatocyte cultures.  Together, these data suggest that 
the SH2B1-IRS physical interaction inhibits IRS dephosphorylation by tyrosine 
phosphatases.  Interestingly, the SH2B1-IRS interaction did not inhibit the ability of 
phosphorylated IRS proteins to bind to p85, the regulatory subunit of PI 3-kinase; in 
contrast, it enhanced insulin-stimulated IRS-p85 association and subsequent Akt 
phosphorylation and activation, presumably by protecting IRS proteins against 
dephosphorylation.  These data suggest that SH2B1 does not compete with p85 for the 
same binding sites in IRS proteins, and that the SH2B1-IRS interaction does not sterically 
interfere with the IRS-p85 interaction.  Therefore, the SH2B1-IRS interaction may 
selectively block IRS interaction with tyrosine phosphatases, thereby inhibiting IRS 
dephosphorylation.  Alternatively, the SH2B1-IRS interaction may alter IRS 
conformation so that multiple tyrosine phosphorylation sites, in addition to SH2B1-bound 
site(s), are resistant to dephosphorylation, but still retain their ability to bind to 
downstream signaling molecules and activate downstream pathways including the PI 3-
kinase/Akt pathway. 
In conclusion, SH2B1 appears to promote insulin sensitivity in animals by 
multiple mechanisms (Fig. 3.6).  Neuronal SH2B1 increases insulin sensitivity indirectly 
by reducing adiposity (23).  In muscle, liver and adipose tissue, SH2B1 binds to IR and 
stimulates IR catalytic activity to globally activate pathways downstream of IR.  SH2B1 
binds to both IRS-1 and IRS-2 and protects IRS proteins from tyrosine 
dephosphorylation, augmenting and/or prolonging IRS protein-mediated pathways.  In 
addition, SH2B1 forms dimers, and each SH2B1 molecule in a SH2B1 dimer may 
simultaneously bind to IR and IRS-1 (or IRS-2), thereby stabilizing IR/IRS-1 (or IR/IRS-
2) complexes.  Therefore, SH2B1 and molecules that mimic these functions of SH2B1 
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Fig. 3.1.  Peripheral SH2B1 enhances insulin sensitivity in mice.  (A-F) WT and TgKO 
male mice (7 wks) were fed a HFD. (A) Growth curve. (B) Body fat content after 16-wks on HFD. (C) 
Fasting (16-h) blood glucose levels and (D) plasma insulin levels after 16-wks on HFD. (E) Glucose 
tolerance tests (GTT) performed on mice fed HFD for 16-wks. (F) Insulin tolerance tests (ITT) performed 









Fig. 3.2. Deletion of peripheral SH2B1 attenuates insulin signaling in mice. WT and 
TgKO males (7 wks) were fed a HFD for 16-wks. Mice were fasted for 16-h and treated with PBS or 
insulin (3 U per mouse). Tissue extracts were prepared 5 min after stimulation. (A) IRS-1 in muscle 
extracts was immunoprecipitated (IP) with anti-IRS-1 antibody (IRS-1) and immunoblotted (IB) with 
anti-phosphotyrosine (pTyr) and p85 antibodies. IR in muscle extracts was immunoprecipitated with 
IR and immunoblotted with pTyr. Muscle extracts were immunoblotted with phospho-specific Akt 
antibodies against phospho-Thr308 (pThr308) or phospho-Ser473 (pSer473) and Akt, respectively. (B) 
IRS-1 and Akt phosphorylation in (A) was quantified by densitometry and normalized to total IRS-1 and 
Akt protein levels, respectively. (C) Liver extracts were immunoprecipitated with IRS-1 and 
immunoblotted with pTyr.  The same blots were reprobed with IRS-1. IRS-1 phosphorylation was 
quantified and normalized to total IRS-1 protein levels. (D) Liver extracts were immunoblotted with 
pSer473 and Akt. Ser473 phosphorylation was quantified and normalized to total Akt protein levels. (E) 
Epididymal fat (WAT) extracts were immunoprecipitated with IRS-1 and immunoblotted with pTyr and 
reprobed with IRS-1.  IRS-1 phosphorylation was normalized to total IRS-1 protein levels.  (F) WAT 
extracts were immunoprecipitated with PAS (anti-phospho-Ser/Thr Akt substrate) and immunoblotted 
with AS160.  Extracts were also immunoblotted with tubulin. Three animals were examined for each 










Fig. 3.3.  SH2B1 directly promotes insulin signaling in cells via its SH2 domain. (A) 
Primary hepatocyte cultures were prepared from WT or KO mice (8 wks) and treated with 100 nM insulin 
for 10 min.  Panel 1: cell extracts were immunoprecipitated with SH2B1 and immunoblotted with 
SH2B1.  Panels 2-3: cell extracts were immunoprecipitated with IR and immunoblotted with pTyr and 
IR.  Panels 4-5: cell extracts were immunoprecipitated with IRS-1 and immunoblotted with pTyr 
orp85.  Panels 6-7: cells extracts were immunoblotted with pSer473 and Akt. (B) IRS-1 and IR were 
transiently coexpressed with empty vector (CON), Myc-tagged SH2B1 or R555E plasmids in HEK293 
cells.  Cells were treated with 100 nM insulin for 10 min and extracts were immunoblotted with indicated 
antibodies. (C) IRS-1 and IR were transiently coexpressed with empty vector (CON), Myc-tagged SH2B1 
or N504 plasmids in HEK293 cells.  Cells were treated with 100 nM insulin for 10 min and extracts were 
immunoblotted with indicated antibodies.  IRS-1 phosphorylation was normalized to total IRS-1 protein 
levels. (D) Shc and IR were transiently coexpressed with empty vector (CON), Myc-tagged SH2B1 or 
N504 plasmids in HEK293 cells.  Cells were treated with 100 nM insulin for 10 min and extracts were 
immunoblotted with indicated antibodies.  Shc phosphorylation was normalized to total Shc protein levels.  















Fig. 3.4A-C.  SH2B1 directly enhances insulin receptor activity in vitro. (A) CHOIR 
cells were treated without or with 100 nM insulin for 10 min.  IR was purified with WGA-agarose beads, 
preincubated with indicated amounts of GST or GST-SH2B1 fusion protein, and subjected to in vitro 
kinase assays with GST-IRS-1 as substrate for 10 min.  Reaction mixtures were immunoblotted with 
pTyr, IRS-1 or IR. (B) WGA-purified IR was preincubated with GST or GST-SH2 fusion protein (5 
g) and subjected to in vitro kinase assays with GST-IRS-1 protein (amino acids 526-859 of rat IRS-1) as 
substrate for 10 min.  IRS-1 phosphorylation was quantified by densitometry and normalized to total GST-
IRS-1 levels. (C) CHOIR cells were treated without or with 100 nM insulin for 10 min.  Cell extracts were 
immunoprecipitated with pTyr.  pTyr-immunopurified IR was preincubated with GST or GST-SH2 
fusion protein (amino acids 524-670) (5 g), and subjected to in vitro kinase assays with GST-IRS-1 as 
substrate for 10 min.  Reaction mixtures were immunoblotted with indicated antibodies and IRS-1 














Fig. 3.4D-E.  SH2B1 directly enhances insulin receptor activity in vitro. (D) WT or 
Y1158F was expressed in COS-7 cells.  Cells were treated with 100 nM insulin for 10 min.  Cell extracts 
were immunoblotted with pTyr or IR. (E) WT or Y1158F was expressed in COS-7 cells and treated with 
insulin.  WT or Y1158F was purified with WGA-agarose beads, preincubated with GST or GST-SH2B1 
fusion protein (5 g), and subjected to in vitro kinase assays with GST-IRS-1 as substrate for 10 min.  






Fig. 3.5.  SH2B1 protects IRS-1 from dephosphorylation. (A) IRS-1 and SH2B1 were 
transiently expressed in HEK293 cells.  Cell extracts were immunoprecipitated with SH2B1 and 
immunoblotted with IRS-1 and SH2B1. (B) CHOIR/IRS-1 cells were stimulated with 100 nM insulin for 
10 min.  IRS-1 was immunoprecipitated with IRS-1, preincubated with GST or GST-SH2B1 (2 g), and 
subjected to in vitro dephosphorylation assays with indicated amounts of alkaline phosphatase for 30 min.  
Reaction mixtures were immunoblotted with pTyr and IRS-1. (C) IR and IRS-1 were transiently 
expressed with PTP1B (0.1 g) and increasing amounts of Myc-tagged SH2B1 (0-0.8 g).  Cells were 
treated with 100 nM insulin for 10 min and extracts were immunoblotted with indicated antibodies. (D) 
IRS-1 was expressed with IR or Y1158F in the absence or presence of SH2B1 in HEK293 cells.  Cells 
were treated with 100 nM insulin for 10 min and extracts were immunoblotted with indicated antibodies. 
(E) IRS-1 (1 g) and Y1158F (1 g) plasmids were transiently cotransfected with or without SH2B1 
plasmids (0.8 g) in HEK293 cells.  Cells were deprived of serum overnight 48 h after transfection, and 
treated with 100 nM insulin for 10 min.  Cell extracts were immunoprecipitated with IRS-1 and 
immunoblotted with p85 and IRS-1.  Extracts were also immunoblotted with indicated antibodies. (F) 
IRS-1 and Y1158F were coexpressed with or without SH2B1.  Cells were treated with 100 nM insulin for 












Fig. 3.6.  A model for SH2B1 regulation of insulin signaling.  In response to insulin, SH2B1 
binds directly to phospho-Tyr1158 in IR via its SH2 domain and stimulates IR kinase activity, thereby 
enhancing the activation of multiple signaling pathways downstream of IR (e.g. the Shc/MAPK and the 
IRS/PI 3-kinase pathways).  SH2B1 also binds to IRS-1 or IRS-2 and inhibits their dephosphorylation on 
tyrosines to specifically promote the activation of IRS protein-mediated pathways.  Since SH2B1 dimerizes 
via its DD domain, dimerized SH2B1 may further enhance insulin signaling by simultaneously binding to 
both IR and IRS-1 to stabilize active IR with IRS-1 or recruit IRS-1 to IR.  PTP: protein tyrosine 
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SH2B1 Supports -cell Function Independent Of Central Leptin Action 
 
Abstract 
Insulin resistance and -cell dysfunction are determinants for diabetes.  Systemic 
disruption of the Sh2b1 gene in mice results in obesity and diabetes.  Neuronal SH2B1 
promotes peripheral insulin sensitivity by regulating leptin sensitivity, energy balance, 
and adiposity.  However, SH2B1 is expressed in insulin-target tissues and in the 
pancreas, raising the possibility that SH2B1 in these tissues may contribute to insulin 
sensitivity and/or -cell function to regulate glucose metabolism.  To test these 
possibilities, we examined glucose metabolism, glucose tolerance and insulin sensitivity 
in two mouse models.  Sh2b1 haploinsufficiency exacerbated the diabetic phenotype in 
leptin-deficient, ob/ob mice.  Insulin resistance was similar in Sh2b1+/-ob/ob and ob/ob 
mice.  However, Sh2b1+/-ob/ob were severely hyperglycemic due to -cell dysfunction.  
Pancreatic insulin content, but not pancreas mass or -cell area, was dramatically reduced 
in Sh2b1+/-ob/ob mice, which likely contributes glucose intolerance and decreased 
postprandial insulin levels in Sh2b1+/-ob/ob mice.  We generated pancreas-specific 
SH2B1-knockout (P-KO) mice to further examine the role of SH2B1 in the pancreas.  P-
KO mice were fed a high-fat diet (HFD) to induce peripheral insulin resistance.  
However, disruption of SH2B1 in the pancreas did not alter glucose tolerance after 10 
weeks of diet-induced obesity.  Collectively, these data suggest that SH2B1 has an 
important leptin-independent role in the regulation of glucose homeostasis.  In the 
pancreas of severely obese mice, SH2B1 supports -cell function, possibly by protecting 




Impaired insulin action in peripheral tissues (insulin resistance) and insufficient 
insulin secretion (-cell dysfunction) contribute to the development of impaired glucose 
tolerance and hyperglycemia, hallmarks of type 2 diabetes.  Insulin resistance is a driving 
force for the development of -cell dysfunction.  In the prediabetic state, -cells initially 
compensate for insulin resistance by increasing both insulin production and secretion (13, 
16, 17, 33).  However, the compensatory capacity of the -cell is limited and -cells 
eventually fail to secrete adequate amounts of insulin, resulting in the development of 
type 2 diabetes. 
Multiple growth factors, including insulin, insulin-like growth factor-1 (IGF-1), 
growth hormone (GH), and prolactin promote -cell function (6, 11, 15, 18, 21-23, 29, 
44, 45).  Many of the intracellular signaling pathways through which these growth factors 
modulate -cell function have been studied.  IGF-1 and insulin activate the IRS-2/PI 3-
kinase/Akt2 pathway, which inhibits FoxO1 activity to promote Pdx1 expression (18, 21, 
23, 29, 44, 45).  Pdx1 is a master transcriptional regulator in -cells that regulates the 
expression of genes necessary for -cell function, as well as those needed for 
proliferation and survival (1-3, 21).  Additionally, activation of the JAK2/STAT 
pathways by GH and prolactin promote -cell function and proliferation (6, 11, 15, 22).  
The adapter protein SH2B1 is expressed in the pancreas (9, 35) and promotes the 
activation of both the IRS-2/PI 3-kinase/Akt2 and JAK2/STAT pathways in cells (5, 25, 
37, 40, 43), raising the possibility that SH2B1 may play a role in -cell function and/or -
cell proliferation.   
SH2B1 is a PH and SH2 domain containing adapter protein that mediates cellular 
responses to a wide range of growth factors and cytokines, including insulin and leptin (8, 
19, 20, 25, 34, 37-40, 43, 47).  Disruption of the Sh2b1 gene in mice causes both obesity 
and diabetes (24, 35, 36).  Genetic evidence indicates that SH2B1 in the brain 
predominantly regulates leptin action to control energy balance (9, 24, 35, 36).  SH2B1-
knockout (KO) mice are severely leptin resistant (24, 35, 36).  However, leptin sensitivity 
is restored, energy balance is corrected, and systemic insulin sensitivity is improved after 
reconstitution of SH2B1 expression in neurons of SH2B1-KO mice (36).  Moreover, 
overexpression of SH2B1 in neurons prevents diet-induced obesity (36), whereas 
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overexpression of a dominant negative mutant of SH2B1 in neurons induces obesity 
(Chapter 2).  Collectively, these findings indicate that SH2B1 in the brain is a leptin 
sensitizer that is critical for regulation of energy balance and body weight.  Moreover, 
SH2B1 in the brain indirectly promotes systemic insulin sensitivity and glucose 
homeostasis by controlling body weight and adiposity. 
In cells, SH2B1 promotes insulin signaling by promoting insulin receptor kinase 
activity and by attenuating dephosphorylation of insulin receptor substrate (IRS) proteins 
(28).  SH2B1 is expressed in insulin-target tissues, including skeletal muscle, liver, and 
white adipose tissue (9, 35), and we recently reported that disruption of SH2B1 in these 
tissues exacerbates diet-induced hyperglycemia, hyperinsulinemia and glucose 
intolerance (28).  These data indicate that peripheral SH2B1 directly regulates insulin 
signaling to promote glucose homeostasis. 
SH2B1 is expressed in the pancreas (9, 35), but whether pancreatic SH2B1 has a 
role -cell function is not known.  The observations that SH2B1 promotes insulin, IGF-1 
and GH signaling in cultured cells (9, 28) raises the possibility that SH2B1 in the 
pancreas may contribute to the regulation of glucose metabolism by supporting -cell 
function.  To test this, we examined glucose metabolism, glucose tolerance and insulin 
sensitivity in two mice models.  First, we generated leptin-deficient (ob/ob) mice with 
Sh2b1 haploinsufficiency (Sh2b1+/- ob/ob mice) to test whether SH2B1 promotes glucose 
metabolism independent of leptin action.  We report that Sh2b1 haploinsufficiency did 
not alter energy metabolism in leptin-deficient mice; however, Sh2b1 haploinsufficiency 
exacerbated the diabetic phenotype in ob/ob mice.  Glucose tolerance was severely 
impaired in Sh2b1+/- ob/ob mice due to -cell dysfunction.  These data support the 
hypothesis that SH2B1 in the pancreas contributes to the regulation of glucose 
homeostasis independent of the ability of SH2B1 in the brain to regulate energy balance.  
To further examine the contribution of SH2B1 in the pancreas to the regulation of 
glucose homeostasis and to test whether SH2B1 in -cells prevents -cell dysfunction 
during diet-induced obesity, we generated pancreas-specific SH2B1-knockout mice (P-
KO).  P-KO mice were fed a high fat diet (HFD) for 10 weeks to induce peripheral 
insulin resistance.  Fed glucose levels were higher in HFD-fed P-KO mice than in HFD-
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fed control mice.  However, fasting glucose levels and glucose tolerance were similar in 
P-KO and control mice.  Together, these data indicate that SH2B1 has an important 
leptin-independent role in the regulation of glucose homeostasis.  In the pancreas, SH2B1 
supports -cell function in genetically obese mice, possibly by protecting -cells from 
oxidative stress induced by glucotoxicity. 
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Materials and Methods 
Generation of leptin-deficient (ob/ob) mice with reduced SH2B1 expression.  
Sh2b1+/- mice have been described previously (9).  Sh2b1+/- mice were backcrossed for 
six generations onto a C57BL/6 genetic background.  Sh2b1+/- mice were crossed to ob/+ 
mice (Jackson Laboratories) to generate double heterozygotes (Sh2b1 +/- ob/+).  Sh2b1 +/- 
ob/+ mice were crossed to generate wild-type (WT), ob/ob, Sh2b1 +/- ob/ob, and 
SH2B1KO ob/ob mice.  Male mice were used for experiments.  Mice were housed on 14-
hour light/10-hour dark cycle in the Unit for Laboratory Animal Medicine at the 
University of Michigan, and were fed standard rodent chow (9% fat; Lab Diet) ad libitum 
with free access to water.  Animal protocols were approved by the University Committee 
on Use and Care of Animals (UCUCA) at the University of Michigan. 
Body composition, energy expenditure, food intake and locomotor activity.  
Fat content was measured by dual energy x-ray absorptiometry (Norland Medical 
System).  Food intake, oxygen consumption (VO2), carbon dioxide production (VCO2), 
and spontaneous locomotor activity were measured using the Comprehensive Laboratory 
Monitoring System (CLAMS, Columbus Instruments).  Mice were individually housed in 
metabolic chambers with free access to food and water.  After 24 hours of acclimation, 
measurements were made continuously for 48 hours.  O2 and CO2 in each chamber were 
sampled for 5 seconds at 10 minute intervals.  Food intake was measured using a 
precision balance attached to the chamber.  Locomotor activity was recorded every 
second in X and Z dimensions. 
Blood glucose, plasma insulin, glucose tolerance tests (GTT) and insulin 
tolerance tests (ITT).  Blood glucose levels were determined using glucometers (Bayer 
Corp).  Plasma insulin was measured using a rat insulin ELISA kit (Crystal Chem).  
Glucose tolerance tests (GTT) and insulin tolerance tests (ITT) were conducted as 
previously described (9, 35, 36). 
Immunoprecipitation and immunoblotting.  Mice were anesthesized with 
Averin (0.5 g of tribromoethanol and 0.25 g or tert-amyl alcohol in 39.5 ml of water; 0.02 
ml/g of body weight).  Tissues were isolated, rapidly frozen in liquid nitrogen, and stored 
at -80 ºC until analysis.  Frozen tissue samples were homogenized in ice cold lysis buffer 
(50 mM Tris HCl, pH 7.5, 0.5% Nonidet P-40, 150 mM NaCl, 2 mM EGTA, 1 mM 
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Na3VO4, 100 mM NaF, 10 mM Na4P2O7, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml 
aprotinin, 10 g/ml leupeptin) and extracts were immunoblotted or immunoprecipitated 
with indicated antibodies. 
Islet morphology and immunoflourescence.  Tissues were fixed in 4% 
paraformaldehyde overnight and protected in 30% sucrose.  Frozen pancreas sections (5-
8 m) were prepared and stained with indicated antibodies.  Immunoflourescence was 
visualized using a BX51 microscope (Olympus) and images were captured using a DP70 
Digital Camera (Olympus). 
-cell area.  To determine -cell area, 4-5 pancreas sections >250 m apart were 
obtained per mouse.  Sections were stained with anti-insulin antibody to label -cells.  
Sections were visualized and images were captured as described above.   cell area (in 
m2) and the area of each section was determined using ImageJ software.   cell area was 
calculated by dividing the area of all insulin-positive cells in the 4-5 sections by total area 
of the 4-5 sections examined for each mouse.  
Insulin content in pancreas.  Pancreata were isolated from fasted (16-h) mice, 
weighed, rapidly frozen in liquid nitrogen and stored at -80 ºC until analysis.  The entire 
pancreas was homogenized in acid-ethanol (1.5% HCl in 70% EtOH), and extracted 
insulin was measured using a rat insulin RIA kit (Millipore).  Insulin content was 
normalized to pancreas wet weight. 
Generation of Sh2b1 flox/flox mice.  Unidirectional loxP sites were introduced into 
a 22 kb fragment of mouse genomic DNA that spanned the coding exons of the Sh2b1 
gene.  One loxP site was inserted into the intron between the second and third exons and 
a second loxP site was inserted into the intron between the fifth and sixth exons in the 
Sh2b1 gene.  A Neo cassette flanked by unidirectional Flp-recombinase recognition (Frt) 
sites was inserted 3’ of the first loxP (between exon 2 and exon 3).  A thymidine kinase 
(TK) expression cassette were included in the targeting vector.  A Hind III restriction site 
was introduced after the 3’ loxP site to facilitate detection of homologous recombination 
by Southern blot analysis. 
The linearized targeting construct was electroporated into R1 ES cells 
(129/Svx129/Sv-CP F1) by staff at the University of Michigan Transgenic Animal Model 
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Core (TAMC) facility.  ES clones were first screened by PCR to detect integration of the 
3’ loxP site.  To confirm that homologous recombination occurred between the targeting 
construct and the Sh2b1 locus, genomic DNA was digested with Hind III and subjected to 
Southern blot analysis.  Two ES cell clones were microinjected into C57BL/6 blastocyts 
to generate chimeric Sh2b1 flox-NEO/+ mice.  Six chimeric (>90% agouti) males from each 
clone were breed to C57BL/6 females to identify germline founders. 
The Neo cassette acts as a transcriptional block in Sh2b1 flox-NEO/+ mice, resulting 
in reduced SH2B1 expression (data not shown).  Therefore, the Neo cassette was deleted 
from the germline by crossing Sh2b1 flox-NEO/+ mice with a Flp deleter strain 
(TgACTFLPe) that ubiquitously expresses Flp recombinase under the control of the 
human actin promoter (Jackson Laboratories) to produce Sh2b1 flox/+ mice.  Sh2b1 flox/+ 
mice were intercrossed to generate mice homozygous for the conditional allele (Sh2b1 
flox/flox). 
Generation of pancreas specific SH2B1-knockout (P-KO) mice.  Pdx1-Cre 
mice in which Cre recombinase is expressed under the control of the mouse Pdx1 
promoter have been described (12).  Pdx1-Cre mice were provided by Dr. Richard 
Mortensen, University of Michigan.  Mice homozygous for the floxed Sh2b1 allele 
(Sh2b1 flox/flox ) were crossed to Pdx1-Cre transgenic mice.  The resultant double 
heterozygous mice were crossed to Sh2b1flox/+ mice to produce pancreas-specific SH2B1-
knockout mice (P-KO mice: Sh2b1 flox/flox/Pdx1-Cre).  The control group (Ctrl) consisted 
of both Sh2b1 flox/flox and Sh2b1 +/+/Pdx1-Cre mice.  P-KO and Ctrl male mice were fed 
either normal rodent chow (9% fat; Lab Diet) or a high fat diet (45% fat; Research Diets) 
ad libitum with free access to water. 
Statistical Analysis.  Data are presented as means  SEM.  Differences between 




Disruption of Sh2b1 in leptin-deficient (ob/ob) mice results in lethality and 
reduced viability.  To explore the leptin-independent regulation of glucose metabolism 
by SH2B1 in vivo, SH2B1-knockout (KO) mice were crossed onto the leptin-deficient 
background in an attempt to generate double mutant mice lacking both SH2B1 and leptin.  
Surprisingly, the number of double mutant Sh2b1-/- ob/ob mice produced from 
heterozygous matings (Sh2b1+/- Ob/ob x Sh2b1+/- Ob/ob) did not reach the expected 
Mendelian ratio indicating that the combined deletion of both SH2B1 and leptin in 
C57BL/6 mice causes either embryonic or perinatal lethality (data not shown).   
Therefore, we chose to examine the effects of Sh2b1 haploinsufficiency on 
glucose metabolism in leptin-deficient mice (Sh2b1+/- ob/ob) mice.  To confirm that 
inactivation of one Sh2b1 allele produced the expected 50% reduction in SH2B1 protein, 
we examined SH2B1 protein levels in brain and liver.  Two isoforms of SH2B1 in brain 
and one isoform of SH2B1 in liver were detected in wild type (WT), ob/ob and Sh2b1+/- 
ob/ob mice (Fig. 4.1A).  Compared to ob/ob mice, SH2B1 levels in both brain and liver 
were reduced in Sh2b1+/- ob/ob mice.  Notably, SH2B1 protein levels were similar in 
brain and liver from wild type (WT) and ob/ob mice (Fig. 4.1A), indicating that leptin-
deficiency does not alter SH2B1 expression in mice.  
Sh2b1 haploinsufficiency does not alter obesity or energy balance in leptin-
deficient mice.  Obesity and dyslipidemia likely contribute to insulin resistance and 
glucose intolerance in SH2B1-KO mice (9, 24, 35, 36), making it difficult to address the 
contribution of SH2B1 in peripheral tissues and pancreas to the regulation of glucose 
metabolism.  Body weight and fat content were similar in ob/ob and Sh2b1+/- ob/ob male 
mice (Fig. 4.1B-C).  The size of individual adipocytes from epididymal fat pads was also 
similar in Sh2b1+/- ob/ob and ob/ob mice (data not shown).  As expected, ob/ob mice 
were hyperphagic and consumed more food than age-matched WT mice; however, Sh2b1 
haploinsufficiency had no additive effect on food intake in Sh2b1+/- ob/ob mice (Fig. 
4.1D).  Moreover, Sh2b1 haploinsufficiency did not alter energy expenditure or activity 
in leptin-deficient mice (Fig. 4.1E-F).  Collectively, these data indicate that a reduction in 
SH2B1 levels is not sufficient to further alter energy imbalance in leptin-deficient mice. 
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Sh2b1 haploinsufficiency exacerbates the diabetic phenotype in leptin-
deficient mice.  SH2B1 is expressed in insulin-target tissues and in the pancreas (9, 35).  
To determine whether SH2B1 in these tissues contributes to the regulation of insulin 
sensitivity and glucose homeostasis in the absence of leptin signaling, glucose and insulin 
levels in ob/ob and Sh2b1+/- ob/ob male mice were compared.  Fasting glucose levels 
were significantly elevated in ob/ob mice as early as seven weeks of age (WT: 64.8 ± 4.8 
mg/dl, n = 9; ob/ob: 138.3 ± 6.5 mg/dl, n = 9); hyperglycemia was further exacerbated in 
Sh2b1+/- ob/ob mice (185.6 ± 16.9 mg/dl, n = 9).  By 12 weeks of age, fasting and 
random fed glucose levels were increased by 150% and 30%, respectfully, in Sh2b1+/- 
ob/ob mice compared to ob/ob mice (Fig. 4.2A).  Fasting insulin levels were similar in 
Sh2b1+/- ob/ob and ob/ob mice (Fig. 4.2B); however, insulin levels in randomly fed 
Sh2b1+/- ob/ob and ob/ob mice were significantly different (Fig. 4.2B).  In the fed state, 
plasma insulin levels were 4.6-times higher in ob/ob mice compared to Sh2b1+/- ob/ob 
mice (ob/ob: 23.2 ± 6.8 ng/ml, n = 5; Sh2b1+/- ob/ob: 5.0 ± 1.3 ng/ml, n = 5; p<0.01).  
Comparing insulin levels in fasted versus fed mice, plasma insulin increased ~5-fold in 
ob/ob mice in response to feeding (fed: 23.2 ± 6.8 ng/ml, n = 5; fasted: 4.7 ± 6.8 ng/ml, n 
= 9); by contrast, insulin levels were nearly identical in fed and fasted Sh2b1+/- ob/ob 
mice (fed: 5.0 ± 1.3 ng/ml, n = 5; fasted: 4.9 ± 1.3 ng/ml, n = 9). 
To examine glucose and insulin sensitivity in Sh2b1+/- ob/ob and ob/ob mice, 
glucose tolerance (GTT) and insulin tolerance tests (ITT) were performed.  Exogenous 
glucose (0.6g D-glucose/kg body weight) caused a sharp rise in glucose levels in both 
ob/ob and Sh2b1+/- ob/ob mice; however, glucose tolerance was more significantly 
impaired in Sh2b1+/- ob/ob mice, as glucose levels remained significantly higher for a 
longer period after the glucose injection (Fig. 4.2C).  Compared to ob/ob mice, the area 
under the GTT curve increased nearly 1.5-times in Sh2b1+/- ob/ob mice (ob/ob: 587.5 ± 
51.6 mg/dl x hr, n = 7; Sh2b1+/- ob/ob: 875.9 ± 88.7 mg/dl x hr, n = 9; p<0.05).  Notably, 
the extent to which glucose tolerance is impaired in Sh2b1+/- ob/ob mice is 
underestimated.  Blood glucose levels in nearly half (3 of 7) of the Sh2b1+/- ob/ob mice 
assayed were higher than the upper detection limit (600 mg/dl) of the glucometers used 
both 30 and 60 minutes after injection; in those three mice, glucose levels were assigned 
a conservative estimate of 600 mg/dl. 
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To examine the extent to which insulin resistance contributed to glucose 
intolerance in Sh2b1+/- ob/ob mice, we conducted insulin tolerance tests (ITT).  Both 
ob/ob and Sh2b1+/- ob/ob mice were severely insulin resistant compared to WT mice and 
required higher doses of insulin to reduce blood glucose.  Insulin (4U/kg body weight) 
reduced glucose levels to a similar extent in ob/ob mice and Sh2b1+/- ob/ob mice, and the 
area under the insulin tolerance curve was similar (Fig. 4.2D).  In younger mice (7-weeks 
of age), insulin (2U/kg body weight) reduced blood glucose levels by ~34% in ob/ob and 
by ~30% in Sh2b1+/- ob/ob within one hour of injection, and the area under the insulin 
tolerance curve was not different (ob/ob: 105.3 ± 3.3 mg/dl x h, n = 5; Sh2b1+/- ob/ob: 
103.5 ± 11.6 mg/dl x h, n = 5).  Taken together, these data indicate that differences in 
insulin resistance do not explain the severe hyperglycemia and glucose intolerance 
observed in Sh2b1+/- ob/ob mice. 
Sh2b1 haploinsufficiency reduces pancreatic insulin content in leptin-
deficient mice.  Severely impaired glucose tolerance and reduced plasma insulin levels in 
fed, hyperglycemic Sh2b1+/- ob/ob mice suggest that -cell function may be regulated by 
SH2B1.  Therefore, we next examined the pancreas and islets from Sh2b1+/- ob/ob and 
ob/ob mice.  -cell area was determined by measuring the area of insulin-positive cells.  
Compared to WT mice, -cell area was increased in ob/ob mice; however, -cell area 
was similar between Sh2b1+/- ob/ob and ob/ob mice (Fig. 4.3A-B), indicating that 
compensatory -cell hyperplasia is not significantly impaired in Sh2b1+/- ob/ob mice.  
Pancreas wet weight was also similar in ob/ob and Sh2b1+/- ob/ob mice (Fig. 4.3C).  
However, pancreatic insulin content was significantly decreased in Sh2b1+/- ob/ob (Fig. 
4.3D).  At 15 weeks of age, pancreatic insulin content was reduced by 69% in Sh2b1+/- 
ob/ob mice (ob/ob: 487.8± 55.5 ng insulin/mg pancreas, n = 8; Sh2b1+/- ob/ob: 151.1 ± 
22.9 ng insulin/mg pancreas, n = 9; P<0.001).  Collectively, these findings suggest that -
cell dysfunction contributes to both impaired glucose tolerance and decreased 
postprandial insulin levels in Sh2b1+/- ob/ob mice.  
SH2B1 is expressed in endocrine pancreas.  SH2B1 is expressed in the 
pancreas (9, 35), but whether SH2B1 is expressed in exocrine or endocrine pancreas has 
not been determined.  Therefore, we examined SH2B1 expression in islets and -cells.  
SH2B1 protein was detected in isolated islets from WT male mice (Fig. 4.4A), and in 
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MIN6 and INS-1 832/13 insulinoma cell lines (data not shown).  To further examine the 
distribution of SH2B1 in the pancreas, pancreas sections from WT and KO mice were co-
immunostained with anti-SH2B1 and anti-insulin antibodies.  SH2B1 was detected in 
pancreas sections from WT, but not KO, mice (Fig.4.4B).  SH2B1 immunoreactivity was 
strongest within the islet (Fig. 4.4B); however, SH2B1 immunoreactivity was largely 
undetected in surrounding acinar and ductal cells (Fig. 4.4B).  These data indicate that 
SH2B1 is highly expressed in islets.  Furthermore, these observations suggest that SH2B1 
may cell autonomously promote insulin production and/or other aspects of -cell biology. 
Generation of pancreas-specific SH2B1-knockout mice.  Multiple growth 
factors, including insulin, insulin-like growth factor-I (IGF-I), growth hormone (GH), and 
prolactin, support -cell function (insulin production and secretion), proliferation and/or 
survival (4, 6, 10, 14, 42, 46).  In cells, SH2B1 is a signaling molecule for all of these 
factors (5, 37, 40, 43).  To examine the role of SH2B1 in the endocrine pancreas, we 
generated pancreas-specific SH2B1-knockout mice (P-KO) (Materials and Methods).  In 
P-KO mice, SH2B1 protein was significantly reduced in pancreas, but present in other 
tissues, confirming that Cre-mediated recombination of the conditional Sh2b1 alleles 
occurred specifically in pancreas (Fig. 4.5A-B).  -cell area and islet morphology was 
similar in P-KO and Sh2b1 flox/flox mice (not shown), suggesting that SH2B1 is not 
required for development of the endocrine pancreas. 
To determine whether SH2B1 in the pancreas is required for glucose metabolism, 
glucose levels in chow-fed P-KO mice (7-8 weeks) were compared to the control (Ctrl) 
group, which consisted of both Sh2b1 flox/flox and Sh2b1 +/+/Pdx1-Cre male mice.  Under 
these experimental conditions, fasting and random fed glucose levels were similar in P-
KO and Ctrl mice (Fig. 4.5C).  Additionally, neither glucose tolerance nor insulin 
sensitivity was altered by pancreas-specific deletion of SH2B1 in P-KO mice (Fig. 4.5D-
E).  Taken together, these data indicate that disruption of Sh2b1 in the pancreas alone is 
not sufficient to alter pancreas development or glucose metabolism in young, chow-fed 
mice. 
Pancreas-specific deletion of SH2B1 causes hyperglycemia, but not glucose 
intolerance in mice fed a high fat diet.  To determine whether deletion of SH2B1 in the 
pancreas alters glucose homeostasis during diet-induced obesity, P-KO and Ctrl mice 
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were fed a high-fat diet (HFD) for 10 weeks.  Body weight (Fig. 4.6A) and fat content 
(not shown) were similar between HFD-fed P-KO and Ctrl mice.  After 10 weeks of diet-
induced obesity, random fed, but not fasting, glucose levels were increased in P-KO mice 
(Fig. 4.6B-C).  Compared to Ctrl mice, blood glucose levels were 40% higher in P-KO 
mice after 10 weeks on HFD (Ctrl: 202.1 ± 18.9 mg/dl, n = 24; P-KO: 289.2 ± 33.59 
mg/dl, n = 13; P<0.02).  As expected insulin resistance was similar between P-KO and 
Ctrl mice (Fig. 4.6D); however, glucose tolerance was not significantly impaired in HFD-
fed P-KO mice relative to Ctrl mice (Fig. 4.6E).  Collectively, these data indicate that 




Insulin resistance and -cell dysfunction are determinants of diabetes.  Systemic 
disruption of the Sh2b1 gene in mice results in obesity and diabetes, demonstrating that 
SH2B1 is required for the maintenance of both energy balance and glucose homeostasis 
(9, 24, 35, 36).  We have demonstrated that SH2B1 in neurons promotes leptin signaling 
and contributes to the intrinsic regulation of energy balance and body weight (36).  By 
regulating energy balance and adiposity, neuronal SH2B1 indirectly promotes whole 
body insulin sensitivity.  Thus, regulation of leptin signaling in the brain may be the 
primary function of SH2B1 in vivo.  However, SH2B1 is expressed in insulin-target 
tissues and in the pancreas (9, 35).  SH2B1 promotes insulin signaling in cultured cells 
and deletion of peripheral SH2B1 exacerbates diet-induced insulin resistance and 
hyperglycemia (28).  These latter observations indicate that SH2B1 directly promotes 
insulin action in peripheral tissues.  However, the role of SH2B1 in the pancreas, and the 
relative contribution of pancreatic SH2B1 in the regulation of glucose metabolism has 
remained largely undefined. 
To test the role of SH2B1 in the pancreas, we examined glucose metabolism, 
glucose tolerance and insulin sensitivity in two mice models.  First, we generated leptin-
deficient (ob/ob) mice with Sh2b1 haploinsufficiency to test whether SH2B1 promotes 
insulin sensitivity and -cell function independent of its role as a leptin signaling 
molecule.  Sh2b1 haploinsufficiency did not alter the onset or severity of obesity in ob/ob 
mice.  However, the diabetic phenotype characteristic of ob/ob mice was dramatically 
exacerbated when SH2B1 was reduced.  Compared to ob/ob mice, Sh2b1+/-ob/ob mice 
were more severely hyperglycemic and glucose intolerant.  However, insulin resistance 
as measured by insulin tolerance tests (ITT), was similar between Sh2b1+/-ob/ob mice and 
ob/ob mice, suggesting that  cell dysfunction, rather than insulin resistance, may 
underlie the dramatic impairment in glucose metabolism. 
Consistent with -cell dysfunction, postprandial plasma insulin levels were 
significantly reduced in Sh2b1+/-ob/ob mice relative to ob/ob mice.  Pancreas mass and -
cell area were similar in Sh2b1+/-ob/ob and ob/ob mice, but pancreatic insulin content 
was dramatically reduced in Sh2b1+/-ob/ob mice.  Therefore, we propose that defects in 
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insulin production largely explain glucose intolerance and the apparent inability of these 
mice to increase postprandial insulin levels.  The extent to which insulin biosynthesis and 
glucose-stimulated insulin secretion is impaired by Sh2b1 haploinsufficiency in -cells of 
Sh2b1+/-ob/ob mice will require further investigation.  Nonetheless, these findings 
provide the first evidence that suggest SH2B1 can promote -cell function in mice. 
 SH2B1 is expressed in the pancreas and SH2B1 expression is highest in islets, so 
we generated pancreas-specific SH2B1-knockout (P-KO) mice to further characterize the 
role of SH2B1 in -cell function.  To accomplish this, mice with conditional (floxed) 
Sh2b1 alleles were crossed with mice expressing Pdx1-Cre mice.  In Pdx1-Cre, the 
expression of Cre recombinase is controlled by the mouse Pdx1 promoter (12).  Pdx1 is 
expressed early in pancreatic development, and Pdx1-Cre has been shown to recombine 
conditional alleles in progenitors that give rise to endocrine, exocrine and ductal cells in 
the pancreas (12).  Therefore, we assume that SH2B1 is deleted in all pancreatic cells in 
P-KO mice.  We chose the Pdx1-Cre line over RIP-Cre mice, in which Cre expression is 
controlled by the rat insulin II promoter.  While the RIP-Cre transgene is predicted to 
drive recombination of the conditional Sh2b1 alleles within -cells, Cre-mediated 
recombination has also been shown to occur in regions of the hypothalamus associated 
with regulation of energy balance (7, 26, 30).  Because recombination of the conditional 
Sh2b1 alleles within the hypothalamus may induce obesity, we chose to avoid this line. 
  P-KO mice were fed a high-fat diet (HFD) to induce peripheral insulin resistance.  
After 10 weeks of diet-induced obesity, peripheral insulin resistance caused 
hyperglycemia in fed, but not fasted, P-KO mice.  However, glucose tolerance was not 
affected by pancreas-specific deletion of SH2B1.  This was somewhat surprising given 
the robust and severe diabetic phenotype in Sh2b1+/-ob/ob mice.  Whether islet area, 
pancreatic insulin content, or glucose-stimulated insulin secretion is altered in HFD-fed 
P-KO mice will require further investigation. 
Nonetheless, it is noteworthy that Sh2b1 haploinsufficiency caused such a severe 
-cell phenotype in ob/ob mice.  Although the underlying mechanism is not clear, one 
possibility is that SH2B1 may increase the antioxidant capacity of -cells.  -cell 
dysfunction is thought to be accelerated by oxidative stressors, such as chronic 
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glucotoxicity and/or lipotoxicity (31, 32).  Thus, -cell dysfunction may be hastened in 
Sh2b1+/-ob/ob mice due to reduced antioxidant capacity.  Interestingly, SH2B1-KO mice 
are more sensitive to low dose streptozotocin (STZ)-induced diabetes than WT mice (S. 
Oka, D. Ren, and L. Rui, unpublished).  Since STZ is thought to generate reactive oxygen 
species (ROS) in -cells (27, 41), these data support this hypothesis.  Future studies are 
required to elucidate the mechanisms by which SH2B1 promotes -cell function and/or 
survival during metabolic stress.  
In summary, SH2B1 promotes glucose metabolism independent of its role as a 
leptin signaling molecule in the brain.  SH2B1 in the pancreas promotes -cell function 
in genetically obese mice.  The extent to which insulin biosynthesis and glucose-
stimulated insulin secretion is impaired by disruption of SH2B1 in -cells will require 
further investigation.  Nonetheless, islets that lack SH2B1 may be susceptible to 
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Fig. 4.1A-C.  Sh2b1 haploinsufficiency does not further alter energy balance in 
leptin-deficient (ob/ob) male mice.  (A)  SH2B1 expression in brain and liver from WT, ob/ob and 
Sh2b1+/-ob/ob male mice (15 wks).  Each lane represents an individual mouse.  (B)  Growth curve.  (C)  
















Fig. 4.1D-F.  Sh2b1 haploinsufficiency does not further alter energy balance in 
leptin-deficient (ob/ob) male mice.  (D)  Food intake.  (E)  Oxygen consumption (VO2).  (F)  














Fig. 4.2A-B.  Sh2b1 haploinsufficiency exacerbates hyperglycemia and glucose 
intolerance in leptin-deficient (ob/ob) male mice.  (A)  Fasting (16-h) and random fed glucose 
levels in male mice (12 wks).  (B)  Fasting (16-h) and random fed plasma insulin levels (12 wks).  The 


















Fig. 4.2C-D.  Sh2b1 haploinsufficiency exacerbates hyperglycemia and glucose 
intolerance in leptin-deficient (ob/ob) male mice.  (D)  Insulin tolerance tests were preformed 
on male mice at 12 wks (4U insulin/kg body weight).  The number of mice per group is indicated in 


















Fig. 4.3.  Insulin content, but not -cell mass, is reduced in Sh2b1+/-ob/ob male 
mice.  (A)  Representative images of pancreas sections stained with insulin antibody.  Scale bar = 
200m.  (B)  Relative -cell area in male mice (15 wks).  The area of insulin-positive cells was normalized 
to total pancreas section area.  4-5 sections were measured per mouse.  (C)  Pancreas wet weight.  (D)  


















Fig. 4.4.  SH2B1 is expressed in islets.  (A)  SH2B1 expression in pancreas and islet extracts from 
WT and SH2B1-knockout (KO) male mice.  (B)  SH2B1 and insulin immunoreactivity in WT and KO 













Fig. 4.5.  Generation of pancreas-specific SH2B1-knockout (P-KO) mice.  (A)  SH2B1 
expression in pancreas extracts from Sh2b1 flox/flox , Sh2b1 +/+/Pdx1-Cre mice, and  P-KO male mice (12 
wks).  SH2B1 in pancreas extracts (1 mg) was immunoprecipitated with anti-SH2B1 antibody (SH2B1) 
and immunoblotted with SH2B1.  In parallel, extracts were immunoblotted with tubulin.  (B)  SH2B1 
expression in pancreas, brain and liver from Sh2b1 flox/flox and P-KO male mice.  SH2B1 in pancreas (1 mg), 
brain (1 mg) and liver (1 mg) was immunoprecipitated with SH2B1 and immunoblotted with SH2B1.  
(C)  Fasting (16-h) blood glucose levels in control (Ctrl) and P-KO male mice.  (D)  GTT performed on 
male mice (7-8 wks).  Mice were fasted overnight (16-h) and D-glucose (2g/ kg body weight) was 
administered by i.p. injection.  (E)  Insulin tolerance tests (ITT) performed on male mice (7-8 wks).  Mice 
were fasted for 6-h and human insulin (1U/kg body weight) was administered by i.p. injection.  The 








Fig. 4.6.  Disruption of Sh2b1 in the pancreas is not sufficient to alter glucose 
homeostasis during diet-induced obesity.  (A-E)  P-KO and Ctrl male mice (7-8 wks) were fed a 
high fat diet (HFD) for 10 wks.  (A)  Growth curve.  (B)  Fasting (16-h) blood glucose levels after 10 wks 
on HFD.  (C)  Random fed blood glucose levels after 10 wks on HFD.  (D)  ITT (1U insulin/kg body 
weight) performed on male mice fed HFD for 10 wks.  (E) GTT (1g D-glucose/kg body weight) performed 
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Conclusions and Future Directions 
 
Conclusions 
SH2B1 is a multifunctional adapter protein expressed in multiple tissues.  Until 
recently, the physiological functions of SH2B1 were largely unknown.  Using genetically 
modified mice, our laboratory has made significant strides in elucidating the essential 
physiological roles of SH2B1.  In this Dissertation, I presented animal and biochemical 
data that indicates SH2B1 regulates insulin sensitivity and glucose homeostasis in mice 
by multiple mechanisms. 
Central SH2B1 indirectly controls insulin sensitivity by regulating energy balance 
Our laboratory previously demonstrated that neuron-specific restoration of 
SH2B1 corrects energy imbalance and prevents obesity in SH2B1-knockout (KO) mice 
(35).  Restoring central SH2B1 in SH2B1-KO mice also improved systemic insulin 
sensitivity, presumably by controlling adiposity (35).  In cultured cells, the SH2 domain 
of SH2B1 alone is sufficient to promote JAK2 activation and leptin signaling.  
Conversely, a dominant negative mutant form of SH2B1 (R555E) that contains a point 
mutation within the SH2 domain blocks both leptin and insulin signaling in cells.  In 
chapter 2, I generated and characterized transgenic mice expressing either truncated 
SH2B1 (504) or mutant SH2B1 (R555E) in neurons to test whether the SH2 domain of 
neuronal SH2B1 is sufficient and necessary for the regulation of body weight in mice.  
Surprisingly, expression of SH2B1 (504) in neurons was not sufficient to prevent the 
development of obesity and obesity associated metabolic disease in SH2B1-KO mice.  
These findings suggest that multiple functional domains within SH2B1 are required for 
neuronal SH2B1 to control energy balance and body weight in mice.
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As expected, SH2B1 (R555E) failed to prevent the development of obesity in 
SH2B1-KO mice, indicating that the SH2 domain of neuronal SH2B1 is required.  
However, overexpression of SH2B1 (R555E) in neurons of wild type mice induced 
obesity and caused insulin resistance.  Interestingly, the onset of obesity in TgR555E 
mice was delayed relative to SH2B1-KO mice, and TgR555E mice were also not as 
heavy as age-matched SH2B1-KO mice.  This finding suggests that mutations in the 
coding region of SH2B1 which alter SH2 domain function may be dominant and result in 
obesity.  In support of this concept, a naturally occurring mutant form of SH2B2, which 
lacks the SH2 domain, but has intact dimerization and PH domains, can bind to SH2B1 
and antagonize the ability of SH2B1 to promote leptin signaling in cultured cells (21). 
Peripheral SH2B1 directly controls insulin sensitivity by regulating insulin signaling 
In chapter 3, I demonstrated that SH2B1 in peripheral tissues contributes directly 
to the regulation of glucose metabolism by promoting insulin signaling in skeletal 
muscle, liver, and white adipose tissue.  We generated TgKO mice that express SH2B1 
only in the brain but not in peripheral tissues (e.g. skeletal muscle, liver, and adipose 
tissue).  Body weight was similar between TgKO and wild type littermates fed either 
normal chow or high fat diet (HFD), consistent with our previous conclusion that 
neuronal SH2B1 controls energy balance and body weight by promoting leptin sensitivity 
(35).  However, loss of peripheral SH2B1 markedly impaired insulin sensitivity 
independent of body weight.  TgKO mice developed hyperglycemia, hyperinsulinemia 
and glucose intolerance to a greater extent than wild type mice fed HFD.  The ability of 
exogenous insulin to reduce blood glucose and to stimulate insulin receptor 
autophosphorylation and activate the IRS/PI3K/Akt pathway in muscle, liver, and white 
adipose tissue was significantly impaired in TgKO mice.  It is interesting to note that this 
insulin resistance phenotype was observed only after TgKO mice are fed HFD.  This 
suggests that peripheral SH2B1 is particularly important for insulin action during bouts of 
overnutrition. 
SH2B1 promotes insulin signaling by multiple mechanisms 
In chapter 3, I examined the molecular mechanisms by which SH2B1 regulates 
insulin signaling and demonstrated that SH2B1 cell autonomously promotes insulin 
signaling by multiple mechanisms.  First, SH2B1 enhances insulin receptor (IR) activity 
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by binding via its SH2 domain to phospho-Tyr1158 in the activation loop of IR.  The SH2 
domain was sufficient to enhance IR activity in vitro, as well as promote the activation of 
signaling pathways downstream of IR.  Interestingly, SH2B1 still enhanced insulin 
signaling in cells with a mutant IR lacking the SH2B1 binding site (Y1158F).  These 
findings led to the subsequent observation that SH2B1 binds to phosphorylated IRS 
proteins, and somehow protects them from dephosphorylation by both recombinant and 
cellular phosphatases.   
Based on these findings, we proposed a new model for how SH2B1 promotes 
insulin action.  First, SH2B1 binds to IR and stimulates IR catalytic activity to globally 
activate downstream signaling pathways.  Second, SH2B1 binds to both IRS-1 and IRS-2 
and protects IRS proteins from tyrosine dephosphorylation, augmenting and/or 
prolonging IRS protein-mediated pathways.  Third, by forming dimers via their 
respective DD domains, each SH2B1 molecule in a SH2B1 dimer could simultaneously 
bind to IR and IRS-1 (or IRS-2), thereby stabilizing IR/IRS-1 (or IR/IRS-2) complexes.   
Pancreatic SH2B1 contributes to  cell function in leptin-deficient mice 
Multiple growth factors promote -cell function and some of these growth factors 
(insulin, IGF-1, prolactin, and GH) utilize SH2B1 as a signaling mediator.  SH2B1 is 
expressed at high levels -cells within the islet, as well as in immortalized -cell lines.  In 
chapter 4, we began to explore the role of SH2B1 in the pancreas in vivo.   
I demonstrated that Sh2b1 haploinsufficiency dramatically exacerbates the 
severity of diabetes, but not obesity, in leptin-deficient (ob/ob) mice.  Although insulin 
resistance was similar in Sh2b1+/-ob/ob and ob/ob mice, Sh2b1+/-ob/ob were severely 
hyperglycemic due to due to -cell dysfunction.  Pancreatic insulin content, but not 
pancreas mass or -cell area, was dramatically reduced in Sh2b1+/-ob/ob mice.  The 
defects in insulin production appear to explain glucose intolerance and the inability of 
these mice to increase postprandial insulin levels.  These data support the overall idea 
that SH2B1 promotes glucose metabolism independent of its role as a leptin signaling 
molecule in the brain.  More importantly, these findings suggest that SH2B1 in the -cell 
is particularly necessary for glucose homeostasis during cases of extreme obesity. 
Although the underlying mechanism for -cell failure in genetically obese mice 
with reduced levels of SH2B1 is not clear, one intriguing possibility is that SH2B1 may 
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protect -cells from gluco- or lipotoxicity, which is thought to contribute to -cell 
dysfunction during obesity (2, 3, 18).  However, pancreas-specific deletion of SH2B1 
alone did not alter glucose homeostasis in mice during diet-induced obesity.  Therefore, 
future studies are required to elucidate the mechanisms by which SH2B1 promotes -cell 
function and/or survival, particularly during metabolic stress.   
Future Directions 
 The studies presented in this dissertation have proved new insight into the role of 
SH2B1 in vivo, particularly with regards to the regulation of systemic insulin sensitivity 
and glucose homeostasis.  Additionally, cell culture studies and biochemical assays 
provided a new model for the regulation of insulin signaling by SH2B1.  However, there 
is still a lot about the role SH2B1 in mammalian physiology that is unknown. 
Regulation of SH2B1 function in health and disease 
 Our findings indicate that SH2B1 functions as both a leptin sensitizer and insulin 
sensitizer in mice.  SH2B1 promotes leptin and insulin action in cells by multiple 
mechanisms, including promoting JAK2 and IR kinase activity and preventing 
dephosphorylation of IRS proteins (10, 22, 30).  Interestingly, overexpression of SH2B1 
can counteract the negative effects of PTP1B on both leptin and insulin signaling in 
cultured cells (30, 34).  Thus, both leptin- and insulin sensitivity may be determined by a 
cellular balance between negative regulators (e.g. PTP1B) and positive regulators 
(SH2B1).  In support of this, PTP1B expression is increased in both leptin- and insulin 
resistant mice (31, 45, 48).  Although SH2B1 is expressed in multiple tissues, relatively 
little is known about whether SH2B1 expression is regulated.  Therefore, it is important 
to determine whether and how SH2B1 expression and/or function are regulated in vivo. 
 SH2B1 protein levels increase in 3T3-L1 preadipocytes during differentiation into 
adipocytes (35, 47), indicating that SH2B1 protein levels can be regulated, at least in 
adipocytes.  Others have reported that SH2B1 mRNA abundance increased in white 
adipose tissue from leptin receptor-deficient (db/db) and from mice fed a high fat diet 
(47); by contrast, preliminary data from our laboratory indicate that SH2B1 protein is 
decreased in white adipose tissue from leptin-deficient (ob/ob) mice (K. Cho and L. Rui, 
unpublished data).  Interpretation of these data is complicated by the observations that 
SH2B1 is expressed in both macrophages and T-cells (8, 20), two populations of cells 
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which infiltrate adipose tissue and accumulate during obesity (23-25, 32).  Thus, it is 
unclear whether data from either study truly reflects changes in SH2B1 expression in 
adipocytes in vivo.  Moreover, it is unclear whether SH2B1 expression is altered in 
hypothalamic neurons, skeletal muscle, liver, or -cells in pathophysiological conditions 
associated with weight gain, insulin resistance, or diabetes. 
 SH2B1 migrates as a broad band on SDS-PAGE gels whereas in vitro 
dephosphorylation of immunopurified SH2B1 with alkaline phosphatase causes SH2B1 
to migrate as a tight band, suggesting that SH2B1 is a phospho-protein which may be 
regulated by post-translational modifications.  SH2B1 is phosphorylated on tyrosine 
residues by JAK2, TrkB, and RET (9, 33, 40, 43).  By contrast, SH2B1 does not appear 
to be a good substrate for IR (D. Morris and L. Rui, unpublished data).  The importance 
of tyrosine phosphorylation of SH2B1 is largely unknown, but one hypothesis is specific 
phosphotyrosines within SH2B1 may provide additional binding sites for other signaling 
molecules. 
SH2B1 also contains multiple serine and threonine residues, which appear to be 
phosphorylated both in the absence and presence of stimulation (37, 39, 40).  One serine, 
Ser 96, has been identified as being phosphorylated by downstream of mitogen-activated 
protein kinase kinase (MEK) (39); however, other specific serine phosphorylation sites in 
SH2B1, and their function, have not been identified.  Serine/threonine phosphorylation of 
SH2B1 may inhibit SH2B1 function and/or alter the affinity of SH2B1 for its binding 
partners, analogous to inhibitory serine/threonine phosphorylation of IRS-1 (1, 19).  
Specifically, phosphorylation of IRS-1 on serine 307 disrupts PTB domain function, 
inhibiting IRS-1 from binding to the IR.  Serine phosphorylation also promotes 
ubiquitination and proteosome-mediated degradation of IRS proteins, limiting the pool of 
available substrate and hindering the ability of insulin to activate the PI3K/Akt pathway 
(46).  Therefore, additional studies are required to identify tyrosine, serine, and threonine 
residues which are phosphorylated and regulate SH2B1 function.  Determining if 
phosphorylation on these sites correlates with either leptin/insulin sensitivity or resistance 
is also critical to understanding the regulation of SH2B1 in health and disease. 
SH2B1 in the central nervous system 
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Our data indicate that SH2B1 in neurons plays a critical role in the regulation of 
energy homeostasis and leptin sensitivity.  The leptin receptor is expressed in multiple 
regions of the brain, including the arcuate nucleus (ARC), the ventromedial (VMH), 
dorsomedial hypothalamic nuclei (DMH), ventral tegmental area (VTA), hippocampus, 
and the brainstem (7, 12-16, 28, 29, 41, 42).  SH2B1 is expressed in the hypothalamus of 
mice, and preliminary immunostaining experiments have demonstrated that SH2-B 
protein is expressed in multiple neurons, including clusters of neurons in the ARC and 
VMH (D. Morris and L. Rui, unpublished data).  However, the identity of SH2B1-
positive neurons has not been determined.  Future studies are needed to determine 
whether SH2B1 is expressed in neuronal populations that are relevant to leptin action. 
Typically, obesity in leptin-signaling impaired mice is a result of both increased 
food intake and decreased energy expenditure.  Surprisingly, SH2B1-KO mice are both 
hyperphagic and have increased energy expenditure; however, subtracting energy 
expenditure from total energy intake indicated that SH2B1-KO mice remain in a net 
positive energy balance, resulting in obesity (34).  Additionally, overexpression of 
dominant negative SH2B1 (R555E) causes increased energy expenditure in mice, 
indicating that this abnormal elevation in energy expenditure is neuronal, rather than 
peripheral, in origin.  One explanation for this aberrant increase in energy expenditure is 
that SH2B1 may differentially regulate leptin sensitivity in hypothalamic neurons 
controlling energy intake versus those controlling energy expenditure.  SH2B1 may be 
required for leptin sensitivity in AgRP/NPY neurons which control energy intake; thus, 
SH2B1 deficiency induces severe leptin resistance in these neurons, resulting in 
hyperphagia and hyperleptinemia.  In contrast, SH2B1 may play a minor role in the 
regulation of neurons that control energy expenditure; therefore, hyperleptinemia in 
SH2B1-KO mice may chronically activate neurons that have normal or only slightly 
impaired leptin sensitivity, resulting in increased energy expenditure.  Consistent with 
this idea, systemic deletion of SH2B1 increases AgRP and NPY expression, whereas 
POMC expression remained normal (34).   
Alternatively, increased energy expenditure in SH2B1-KO and TgR555E mice 
may be leptin-independent.  SH2B1 is a signaling molecule for a number of 
neurotrophins, including brain-derived neurotrophic factor (BDNF) (6, 27, 33, 43).  
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Interestingly, BDNF haploinsufficiency or conditional deletion of BDNF in neurons 
results in leptin resistance, hyperphagia, and weight gain, as well as inter-male 
aggressiveness and increased locomoter activity (17, 26, 36).  All of these phenotypes, 
including increased aggressiveness (L. Jiang and L. Rui, unpublished data), have been 
observed in SH2B1-KO mice, suggesting that the BDNF-regulated processes are also 
impaired in the absence of SH2B1.  Interestingly, preliminary data indicate that 
conditional deletion of SH2B1 in neurons expressing the leptin receptor causes leptin 
resistance, hyperphagia, and obesity, but not aggressiveness in male mice (L. Jiang and L. 
Rui, unpublished data).  This suggests that SH2B1 may independently promote both 
leptin and BDNF regulated processes in neurons.   
Nerve growth factor (NGF) is critical for neuronal differentiation and survival and 
for synaptic plasticity (4).  SH2B1 has been shown to promote both neurite outgrowth 
and neuronal differentiation in response to NGF (5, 11, 33, 38, 44).  Whether NGF 
signaling is impaired in neurons lacking SH2B1 has not been explored.  Thus, it is 
possible that impaired NGF signaling in SH2B1-KO mice may contribute to the obesity 
phenotype by altering the development of the neural circuitry that regulates energy 
homeostasis.   
In summary, these possibilities suggest that neuronal SH2B1 not only regulates 
leptin action but possibly other processes in the central nervous system to control body 
weight.  Regulation of BDNF and NGF signaling by central SH2B1 needs to be explored 
to fully appreciate the role of SH2B1 in neurons. 
SH2B1 in individual tissues 
 To address the role of SH2B1 in individual tissues, we have generated conditional 
SH2B1-KO mice using the Cre/loxP system (chapter 4).  Unidirectional loxP sites were 
introduced into the Sh2b1 locus in mice by homologous recombination.  These mice will 
be used to delete SH2B1 in specific neurons, as well as the liver, skeletal muscle, white 
adipose tissue, and -cells.  To date, we have generated mice lacking SH2B1 in leptin-
receptor expressing neurons, liver, and pancreas.  Selective deletion of SH2B1 in leptin-
receptor expressing neurons in mice (SH2B1-LRb-KO mice) results in obesity, further 
supporting our previous conclusions that SH2B1 is required for leptin sensitivity and 
regulation of body weight (L. Jiang and L. Rui, unpublished data).  By contrast, deletion 
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of SH2B1 specifically in the liver (Y. Zhou and L. Rui, unpublished data) or in the 
pancreas (Chapter 4) resulted in very mild phenotypes, indicating that the collective 
actions of SH2B1 in multiple tissues may contribute to systemic insulin sensitivity and 
regulation of glucose homeostasis.  Additional studies are required to examine the 
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